WO2011025541A1 - Cannabinoid receptor modulators - Google Patents

Cannabinoid receptor modulators Download PDF

Info

Publication number
WO2011025541A1
WO2011025541A1 PCT/US2010/002360 US2010002360W WO2011025541A1 WO 2011025541 A1 WO2011025541 A1 WO 2011025541A1 US 2010002360 W US2010002360 W US 2010002360W WO 2011025541 A1 WO2011025541 A1 WO 2011025541A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
methyl
phenyl
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/002360
Other languages
English (en)
French (fr)
Inventor
Robert M. Jones
Sangdon Han
Lars Thoresen
Jae-Kyu Jung
Sonja Strah-Pleynet
Xiuwen Zhu
Yifeng Xiong
Dawei Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN2474DEN2012 priority Critical patent/IN2012DN02474A/en
Priority to EP10757325A priority patent/EP2470508A1/en
Priority to AU2010286988A priority patent/AU2010286988B2/en
Priority to EP22160034.9A priority patent/EP4036089A1/en
Priority to KR1020177016103A priority patent/KR20170072358A/ko
Priority to KR1020217014027A priority patent/KR20210057213A/ko
Priority to MX2012002499A priority patent/MX2012002499A/es
Priority to KR1020227032376A priority patent/KR102682216B1/ko
Priority to JP2012526732A priority patent/JP5746698B2/ja
Priority to EP22159802.2A priority patent/EP4036082A1/en
Priority to KR1020187029637A priority patent/KR20180115807A/ko
Priority to SG2012013967A priority patent/SG178907A1/en
Priority to CA2770866A priority patent/CA2770866C/en
Priority to NZ598288A priority patent/NZ598288A/en
Priority to EA201270336A priority patent/EA023586B1/ru
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Priority to KR1020127007857A priority patent/KR101749778B1/ko
Priority to KR1020207001281A priority patent/KR20200008045A/ko
Priority to US13/392,074 priority patent/US8778950B2/en
Priority to EP18150186.7A priority patent/EP3363788A1/en
Priority to CN201080049159.2A priority patent/CN102596913B/zh
Priority to BR112012008159A priority patent/BR112012008159A2/pt
Publication of WO2011025541A1 publication Critical patent/WO2011025541A1/en
Priority to IL218130A priority patent/IL218130A/en
Anticipated expiration legal-status Critical
Priority to US13/616,918 priority patent/US9944606B2/en
Priority to US15/912,700 priority patent/US20180354907A1/en
Priority to US16/580,697 priority patent/US11214548B2/en
Priority to US17/024,752 priority patent/US11746091B2/en
Priority to US17/520,952 priority patent/US20220306586A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Definitions

  • the present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB 2 receptor.
  • the present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CBi receptor and the CB 2 receptor.
  • Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics, and pain associated with a disorder selected from: osteoarthritis, cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and autoimmune conditions;
  • autoimmune disorders for example an autoimmune disorder selected from the group consisting of: multiple sclerosis, Guillan-Barre syndrome, polyradiculoneuropathy, chronic inflammatory demyelination, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis, and reactive arthritis;
  • allergic reactions for example, an allergic reaction associated with a disorder selected from: atopic dermatitis, pruritis, urticaria, asthma, conjunctivitis, allergic rhinitis, and anaphylaxis;
  • CNS inflammation for example, CNS inflammation associated with a disorder selected from: Alzheimer's disease, stroke, dementia, amyotrophic lateral sclerosis, and human
  • immunodeficiency virus atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.
  • Cannabinoids are a group of extracellular signaling molecules that are found in both plants and animals. Signals from these molecules are mediated in animals by two G-protein coupled receptors, Cannnabinoid Receptor 1 (CB 1 ) and Cannabinoid Receptor 2 (CB 2 ).
  • CB 1 is expressed most abundantly in the neurons of the CNS but is also present at lower concentrations in a variety of peripheral tissues and cells (Matsuda, L. A. et al. (1990) Nature 346:561-564).
  • CB 2 is expressed predominantly, although not exclusively, in non-neural tissues, e.g.
  • CB is believed to be primarily responsible for mediating the psychotropic effects of cannabinoids on the body, whereas CB 2 is believed to be primarily responsible for most of their non-neural effects.
  • One aspect of the present invention encompasses certain pyrazole derivatives selected from compounds of Formula Ia and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from: H and C 1 -C 6 alkyl;
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R n -R 12 -R 13 ; wherein:
  • R 10 is selected from: C 1 -C 6 alkylene, heteroarylene, and heterocyclylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and C 1 -C 6 alkylene; or R 11 is absent;
  • R 12 is C 1 -C 6 alkylene; or R 12 is absent;
  • R 13 is selected from: C 1 -C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said C 1 -C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: C 1 -C 6 alkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonyl, amino, C 3 -C 7 cycloalkyl, cyano, C 2 -C 8 dialkylamino, C 1 -C 6 haloalkyl, halogen, and hydroxyl;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: C 1 -C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said C 1 -C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said C 1 - C 6 alkyl and aryl are optionally substituted with one substituent selected from: Ci-C 6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH-, -C(O)-, -C(O)O-, C 1 -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with C 1 -C 6 alkyl; or R 15 is absent;
  • R 16 is C 1 -C 6 alkylene; or R 16 is absent;
  • R 17 is selected from: H, C 1 -C 6 alkoxy, Ci-C 6 alkyl, C 1 -C 6 alkylamino, Ci-C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- Ci-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -C 11 bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -Cg dialkylamino, C 2 -Cg dialkylsulfonamide, C 1 -C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said CpC 6 alkylamino, amino, aryl, arylamino, ary
  • R 9 is selected from H, C 1 -C 6 alkyl, and C 3 -C 7 cycloalkyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: Carbo-C]-C 6 -alkoxy, Ci-C 6 alkoxy, C 1 -C 6 alkyl, aryl, CaAo-C 1 -C 6 - alkoxy, C 1 -C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl;
  • aryl, C r C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, C 1 -C 6 alkoxy, halogen, and hydroxyl.
  • One aspect of the present invention encompasses certain pyrazole derivatives selected from compounds of Formula Ia and pharmaceutically acceptable salts, solvates, and hydrates thereof:
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from: H and C 1 -C 6 alkyl; X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R ⁇ -R 12 -R 13 ; wherein:
  • R 10 is selected from: Ci-C 6 alkylene, heteroarylene, and heterocyclylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and C 1 -C 6 alkylene; or R 11 is absent;
  • R 12 is C 1 -C 6 alkylene; or R 12 is absent;
  • R 13 is selected from: Cj-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said C 1 -C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: Q-C 6 alkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkylsulfonyl, amino, C 3 -C 7 cycloalkyl, cyano, C 2 -C 8 dialkylamino, C 1 -C 6 haloalkyl, halogen, and hydroxyl;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: C]-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said C 1 -C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said C 1 - C 6 alkyl and aryl are optionally substituted with one substituent selected from: C 1 -C 6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH-, -C(O)-, C 1 -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with C 1 -C 6 alkyl; or R 15 is absent;
  • R 16 is Cj-C 6 alkylene; or R 16 is absent;
  • R 17 is selected from: H, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, Q-C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- Ci-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, Cs-Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, Ci-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, aryl, arylamino, aryloxy,
  • cycloalkylamino, heteroaryl, heterobicyclyl, heterocyclyl and ureyl are each optionally substituted with one or more substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, Ci-C 6 alkyl, Ci-C 6 alkylsulfonyl, amino, aryl, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 8 dialkylamino, Ci-C 6 haloalkoxy, Ci-C 6 haloalkyl, halogen, heteroaryl, heterocyclyl, and hydroxyl; and
  • R 9 is selected from H, Q-C 6 alkyl, and C 3 -C 7 cycloalkyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: Carbo-Ci-C 6 -alkoxy, Q-C 6 alkoxy, Ci-C 6 alkyl, aryl, carbo-Q-C 6 - alkoxy, C]-C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl; wherein said aryl, Ci-C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, halogen, and hydroxyl.
  • One aspect of the present invention relates to processes for preparing pharmaceutical compositions comprising admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • One aspect of the present invention relates to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
  • One aspect of the present invention relates to method for the treatment of a cannabinoid receptor-mediated disorder in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of a CB 2 receptor-mediated disorder in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of a C-VCB 2 receptor-mediated disorder in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of pain in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of bone and joint pain in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of bone pain in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of joint pain in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of pain associated with osteoarthritis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of osteoarthritis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of osteoporosis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of hyperalgesia in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of allodynia in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of
  • inflammatory pain in an individual comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of
  • inflammatory hyperalgesia in an individual comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of neuropathic pain in an individual, comprising administering to said individual in need thereof, a
  • One aspect of the present invention relates to a method for the treatment of neuropathic hyperalgesia in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of acute nociception in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of muscle pain in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of dental pain in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of migraine and other headache pain in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of pain that occurs as an adverse effect of therapeutics in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of pain associated with a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and autoimmune conditions, in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of multiple sclerosis-associated spasticity in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of autoimmune disorders in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of an autoimmune disorder selected from the group consisting of: multiple sclerosis, Guillan-Barre syndrome, polyradiculoneuropathy, chronic inflammatory demyelination, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis, and reactive arthritis, in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • an autoimmune disorder selected from the group consisting of: multiple sclerosis, Guillan-Barre syndrome, polyradiculoneuropathy, chronic inflammatory demyelination, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis, and reactive arthritis
  • One aspect of the present invention relates to a method for the treatment of allergic reactions in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of an allergic reaction associated with a disorder selected from: atopic dermatitis, pruritis, urticaria, asthma, conjunctivitis, allergic rhinitis, and anaphylaxis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of CNS inflammation in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of CNS inflammation associated with a disorder selected from: Alzheimer's disease, stroke, dementia, amyotrophic lateral sclerosis, and human immunodeficiency virus, in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of
  • Atherosclerosis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of undesired immune cell activity and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus, in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of age-related macular degeneration in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of cough in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of leukemia in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of lymphoma in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of CNS tumors in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of prostate cancer in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of Alzheimer's disease in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of stroke- induced damage in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of dementia in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to a method for the treatment of amyotrophic lateral sclerosis in an individual, comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • a method for the treatment of Parkinson's disease in an individual comprising administering to said individual in need thereof, a therapeutically effective amount of a compound of the present invention.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of a cannabinoid receptor- mediated disorder.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of a CB 2 receptor-mediated disorder.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of a CB 1 ZCB 2 receptor-mediated disorder.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of pain.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of bone and joint pain.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of bone pain.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of joint pain.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of pain associated with osteoarthritis.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of osteoarthritis.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of osteoporosis.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of hyperalgesia.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of allodynia.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of inflammatory pain.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of inflammatory hyperalgesia.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of neuropathic pain.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of neuropathic hyperalgesia.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of acute nociception.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of muscle pain.
  • One aspect of the present invention relates to the use of a compound of the present invention m the manufacture of a medicament for the treatment of dental pain.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of migraine and other headache pam.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of pain that occurs as an adverse effect of therapeutics.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of pain associated with a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and autoimmune conditions.
  • a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and autoimmune conditions.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of multiple sclerosis-associated spasticity.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of autoimmune disorders.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of an autoimmune disorder selected from the group consisting of: multiple sclerosis, Guillan-Barre syndrome,
  • polyradiculoneuropathy chronic inflammatory demyelmation, rheumatoid arthritis, pso ⁇ atic arthritis, ankylosing spondylarthritis, and reactive arthritis.
  • One aspect of the present invention relates to the use of a compound of the present invention m the manufacture of a medicament for the treatment of allergic reactions.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of an allergic reaction associated with a disorder selected from: atopic dermatitis, pru ⁇ tis, urticaria, asthma, conjunctivitis, allergic rhinitis, and anaphylaxis.
  • a disorder selected from: atopic dermatitis, pru ⁇ tis, urticaria, asthma, conjunctivitis, allergic rhinitis, and anaphylaxis.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of CNS inflammation.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of CNS inflammation associated with a disorder selected from: Alzheimer's disease, stroke, dementia, amyotrophic lateral sclerosis, and human immunodeficiency virus.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of atherosclerosis.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of undesired immune cell activity and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus.
  • a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of age-related macular degeneration.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of cough.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of leukemia.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of lymphoma.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of CNS tumors.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of prostate cancer.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of Alzheimer's disease.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of stroke-induced damage.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of dementia.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of amyotrophic lateral sclerosis.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of Parkinson's disease.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of a cannabinoid receptor-mediated disorder.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of the human or animal body by therapy.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of a CB 2 receptor-mediated disorder.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of a CB 1 ZCB 2 receptor-mediated disorder.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of pain.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of bone and joint pain.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of bone pain.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of joint pain.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of pain associated with osteoarthritis.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of osteoarthritis.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of osteoporosis.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of hyperalgesia.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of allodynia.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of inflammatory pain.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of inflammatory hyperalgesia.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of neuropathic pain.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of neuropathic hyperalgesia.
  • One aspect of the present invention relates to compounds of the present invention for method of treatment of acute nociception.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of muscle pain.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of dental pain.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of migraine and other headache pain.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of pain that occurs as an adverse effect of therapeutics.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of pain associated with a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and autoimmune conditions.
  • a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and autoimmune conditions.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of multiple sclerosis-associated spasticity.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of autoimmune disorders.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of an autoimmune disorder selected from the group consisting of: multiple sclerosis, Guillan-Barre syndrome, polyradiculoneuropathy, chronic inflammatory demyelination, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis, and reactive arthritis.
  • an autoimmune disorder selected from the group consisting of: multiple sclerosis, Guillan-Barre syndrome, polyradiculoneuropathy, chronic inflammatory demyelination, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis, and reactive arthritis.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of allergic reactions.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of an allergic reaction associated with a disorder selected from: atopic dermatitis, pruritis, urticaria, asthma, conjunctivitis, allergic rhinitis, and anaphylaxis.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of CNS inflammation.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of CNS inflammation associated with a disorder selected from: Alzheimer's disease, stroke, dementia, amyotrophic lateral sclerosis, and human
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of atherosclerosis.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of undesired immune cell activity and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus.
  • a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of age-related macular degeneration.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of cough.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of leukemia.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of lymphoma.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of CNS tumors.
  • One aspect of the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of prostate cancer.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of Alzheimer's disease.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of stroke-induced damage.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of dementia.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of amyotrophic lateral sclerosis.
  • One aspect of the present invention relates to compounds of the present invention for use in a method of treatment of Parkinson's disease.
  • Figure 1 shows the effect of Compound 493 in the FCA-induced hyperalgesia model of inflammatory pain in rats at 1 h post dosing. See Example 7.
  • Figure 2 shows the effect of Compound 493 in the monosodium iodoacetate (MIA) model of osteoarthritis in rats at 1 h post dosing. See Example 5.
  • Figure 3 shows the effect of 10 mg/kg of Compound 493 on paclitaxel -induced allodynia in rats. See Example 8.
  • Figure 4 shows the effect of Compound 493 on the skin incision model of postoperative pain in rats. See Example 6.
  • Figure 5 shows the effect of Compound 455 on body temperature and locomotor activity in rats. See Example 9.
  • Figure 6 shows the effect of Compound 660 on body temperature and locomotor activity in rats. See Example 9.
  • Figure 7 shows the effect of Compound 700 on body temperature and locomotor activity in rats. See Example 9.
  • Figure 8 shows the effect of Compound 667 on body temperature and locomotor activity in rats. See Example 9.
  • Figure 9 shows a general synthesis of compounds of the present invention wherein X is CC(O)N(R 8 )R 9 and Y is NR 7 .
  • a 2-(but-3-enyl)oxirane derivative is cyclized by treatment with a base.
  • the resulting bicyclic alcohol is oxidized to the ketone and reacted with a dialkyl oxalate derivative in the presence of a base.
  • the pyrazole ring is then formed by reaction with a substituted hydrazine and the resulting ester is hydrolyzed and coupled with an amine to form compounds of the present invention.
  • Figure 10 shows a general synthesis of compounds of the present invention in which R 7 is a 4-oxy-pyrazin-2-yl group.
  • Figure 11 shows a general synthesis of compounds of the present invention similar to the one shown in Figure 9 except the group R 7 is introduced subsequent to the formation of a tri- substituted pyrazole.
  • Figure 12 shows a general synthesis of compounds of the present invention in which R 7 is either a 5-substituted-pyridin-2-yl group or a 5-substituted-pyrazin-2-yl group.
  • Figure 13 shows a general synthesis of compounds of the present invention in which R 7 is a 4-substituted-pyridin-2-yl group.
  • Figure 14 shows a general synthesis of compounds of the present invention wherein X is NR 7 and Y is CC(O)N(R 8 )R 9 .
  • a bicyclo[3.1.0]hexan-3 -ol derivative is oxidized and the resulting ketone is reacted with a dialkyl oxalate derivative in the presence of a base.
  • the pyrazole ring is then formed by reaction with a substituted hydrazine and the resulting ester is hydrolyzed and coupled with an amine to form compounds of the present invention.
  • Figure 15 shows a differential scanning calorimetry (DSC) thermogram for a sample containing a crystalline form of Compound 699 CH 2 Cl 2 solvate and a thermogravimetric analysis (TGA) thermogram of a sample containing a crystalline form of Compound 699 CH 2 Cl 2 solvate.
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Figure 16 shows an overlay of a powder X-ray diffraction pattern (PXRD) for a sample containing a crystalline form of Compound 699 CH 2 Cl 2 solvate obtained from recrystallization using CH 2 Cl 2 /hexane (Top Trace) and a powder X-ray diffraction pattern (PXRD) for a sample containing a crystalline form of Compound 699 CH 2 Cl 2 solvate obtained by slurrying non- solvated Compound 699 in CH 2 Cl 2 (Bottom Trace).
  • the PXRD showed the crystalline solvate obtained from the CH 2 Cl 2 slurry is substantially indistinguishable from the crystalline solvate resulting from recrystallized from CH 2 Cl 2 /hexane.
  • Figure 17 shows the effect of Compound 699 (10 mpk) compared to vehicle (methyl cellulose) in the STZ-induced PDPN Model. See Example 12.
  • Figure 18 shows the effect of Compound 919 (10 mpk) compared to vehicle (methyl cellulose) in the STZ-induced PDPN Model. See Example 12.
  • agonist is intended to mean a moiety that interacts with and activates a G- protein-coupled receptor, for instance a cannabinoid receptor, and can thereby initiate a physiological or pharmacological response characteristic of that receptor.
  • a G- protein-coupled receptor for instance a cannabinoid receptor
  • an agonist may activate an intracellular response upon binding to a receptor, or enhance GTP binding to a membrane.
  • antagonist is intended to mean a moiety that competitively binds to the receptor at the same site as an agonist (for example, the endogenous ligand), but which does not activate the intracellular response initiated by the active form of the receptor and can thereby inhibit the intracellular responses by an agonist or partial agonist.
  • An antagonist does not dimmish the baseline intracellular response in the absence of an agonist or partial agonist.
  • hydrate as used herein means a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non- covalent intermolecular forces.
  • solvate means a compound of the invention or a salt, thereof, that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non- covalent intermolecular forces.
  • Preferred solvents are volatile, non-toxic, and/or acceptable for administration to humans in trace amounts.
  • in need of treatment and the term “in need thereof when referring to treatment are used interchangeably to mean a judgment made by a caregiver (e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of a caregiver's expertise, but that includes the knowledge that the individual or animal is ill, or will become ill, as the result of a disease, condition or disorder that is treatable by the compounds of the invention. Accordingly, the compounds of the invention can be used in a protective or preventive manner; or compounds of the invention can be used to alleviate, inhibit or ameliorate the disease, condition or disorder.
  • a caregiver e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals
  • mice rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • inverse agonist is intended to mean a moiety that binds to the endogenous form of the receptor or to the constitutively activated form of the receptor and which inhibits the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of an agonist or partial agonist, or decreases GTP binding to a membrane.
  • the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50% and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist.
  • modulate or modulating is intended to mean an increase or decrease in the amount, quality, response or effect of a particular activity, function or molecule.
  • composition is intended to mean a composition comprising at least one active ingredient; including but not limited to, salts, solvates, and hydrates of compounds of the present invention, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
  • a mammal for example, without limitation, a human.
  • terapéuticaally effective amount is intended to mean the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician or caregiver or by an individual, which includes one or more of the following:
  • Preventing the disease for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;
  • Inhibiting the disease for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or
  • Ameliorating the disease for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
  • Ci-C 4 acyl is intended to mean a radical comprising a Ci-C 4 alkyl group attached to the carbon of a carbonyl group, wherein C 1 -C 4 alkyl has the same definition as found herein. Examples include, but are not limited to acetyl, propionyl, butyryl, isobutyryl, pivaloyl, and the like.
  • amino is intended to mean the group -NH 2 .
  • aryl is intended to mean a ring system containing 6 to 10 carbon atoms, that may contain a single ring or two fused rings, and wherein at least one ring is aromatic. Examples include phenyl, indanyl, and naphthyl.
  • arylamino is intended to mean a radical comprising an aryl group, attached to a nitrogen, wherein aryl has the same definition as found herein. Examples include, but are not limited to, phenylamino and naphthylamino.
  • arylcarbonyl is intended to mean a radical comprising an aryl group, attached to the carbon atom of a carbonyl group, wherein aryl has the same definition as found herein. Examples include, but are not limited to, benzoyl and naphthylcarbonyl.
  • aryloxy is intended to mean a radical comprising an aryl group, attached to an oxygen, wherein aryl has the same definition as found herein. Examples include, but are not limited to, phenoxy and naphthyloxy.
  • Ci-C 6 alkoxy is intended to mean a radical comprising a Q-C 6 alkyl group attached directly to an oxygen atom, wherein C]-C 6 alkyl has the same definition as found herein. Some embodiments contain 1 to 5 carbons. Some embodiments contain 1 to 4 carbons. Some embodiments contain 1 to 3 carbons. Some embodiments contain 1 or 2 carbons.
  • Examples include, but are not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t- butoxy, isobutoxy, s-butoxy, and the like.
  • Ci-C 6 alkoxycarbonyl is intended to mean a radical comprising a single Ci- C 6 alkoxy group attached to the carbon of a carbonyl group, wherein Ci -C 6 alkoxy has the same definition as found herein.
  • the alkoxycarbonyl group may be represented by the following: alkyl
  • Ci-C 6 alkyl is intended to mean a straight or branched carbon radical containing 1 to 6 carbons. Some embodiments contain 1 to 5 carbons. Some embodiments contain 1 to 4 carbons. Some embodiments contain 1 to 3 carbons. Some embodiments contain 1 or 2 carbons.
  • alkyl group examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, /-butyl, pentyl, isopentyl, ?-pentyl, neopentyl, 1 -methylbutyl [i.e., -CH(CH 3 )CH 2 CH 2 CH 3 ], 2-methylbutyl [i.e., -CH 2 CH(CH 3 )CH 2 CH 3 ], w-hexyl, and the like.
  • the term "Ci-C 4 alkyl" is intended to mean a straight or branched carbon radical containing 1 to 4 carbons.
  • Some embodiments contain 1 to 3 carbons. Some embodiments contain 1 or 2 carbons.
  • Examples of an alkyl group include, but are not limited to, methyl, ethyl, M-propyl, isopropyl, n-butyl, s-butyl, isobutyl, f-butyl, and the like.
  • Ci-C 6 alkylamino is intended to mean a radical comprising one Ci-C 6 alkyl group attached to an NH group, wherein Ci-C 6 alkyl has the same meaning as described herein. Some examples include, but are not limited to, methylamino, ethylamino, «-propylamino, isopropylamino, n-butylamino, .s-butylamino, isobutylamino, f-butylamino, and the like. Some embodiments are "Ci-C 2 alkylamino.”
  • Ci-C 6 alkylcarboxamide is intended to mean a single Ci-C 6 alkyl group attached to either the carbon or the nitrogen of an amide group, wherein Ci -C 6 alkyl has the same definition as found herein.
  • the C r C 6 alkylcarboxamido group may be represented by the following:
  • Examples include, but are not limited to, N-methylcarboxamide, N-ethylcarboxamide, N-w- propylcarboxamide, N-isopropylcarboxamide, N- «-butylcarboxamide, N-s-butylcarboxamide, N- isobutylcarboxamide, N-/-butylcarboxamide, and the like.
  • Cj-C 6 alkylene is intended to mean a straight or branched, saturated aliphatic, divalent radical having 1 to 6 carbon atoms. Some embodiments contain 1 to 5 carbons. Some embodiments contain 1 to 4 carbons. Some embodiments contain 1 to 3 carbons. Some embodiments contain 1 or 2 carbons.
  • Examples include, but are not limited to, methylene, ethylene, «-propylene, isopropylene, n-butylene, s-butylene, isobutylene, f-butylene, pentylene, isopentylene, f-pentylene, neopentylene, 1 -methylbutylene [i.e., -CH(CH 3 )CH 2 CH 2 CH 3 ], 2- methylbutylene [i.e., -CH 2 CH(CH 3 )CH 2 CH 3 ], n-hexylene, and the like.
  • Ci-C 6 alkylsulfonyl is intended to mean a radical comprising a Ci-C 6 alkyl group attached to the sulfur of a sulfonyl group, wherein the Ci-C 6 alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, M-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, s-butylsulfonyl,
  • C 5 -Cn bicycloalkyl is intended to mean a radical comprising two fused or bridged, saturated rings containing 5 to 11 ring carbon atoms.
  • Examples of a bicycloalkyl group include, but are not limited to, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, and the like.
  • C 3 -C 6 cycloalkenylene is intended to mean is intended to mean a mono unsaturated ring di-radical containing 3 to 7 carbons. Some embodiments contain 3 to 6 carbons. Some embodiments contain 3 to 5 carbons. Some embodiments contain 5 to 7 carbons. Some embodiments contain 3 to 4 carbons. Examples include cyclopropenediyl, cyclobutenediyl, cyclopentenediyl, cyclohexenediyl, cycloheptenediyl, and the like.
  • C 3 -C 7 cycloalkyl is intended to mean a saturated ring radical containing 3 to 7 carbons. Some embodiments contain 3 to 6 carbons. Some embodiments contain 3 to 5 carbons. Some embodiments contain 5 to 7 carbons. Some embodiments contain 3 to 4 carbons. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
  • C 3 -C 7 cycloalkylamino is intended to mean a radical comprising a C 3 -C 7 cycloalkyl attached the nitrogen of an amino group, wherein C 3 -C 7 cycloalkyl has the same definition as found herein. Examples include, but are not limited to, cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, and the like.
  • C 3 -C 7 cycloalkylene is intended to mean a saturated ring di-radical containing 3 to 7 carbons. Some embodiments contain 3 to 6 carbons. Some embodiments contain 3 to 5 carbons. Some embodiments contain 5 to 7 carbons. Some embodiments contain 3 to 4 carbons. Examples include cyclopropanediyl, cyclobutanediyl, cyclopentanediyl, cyclohexanediyl, cycloheptanediyl, and the like.
  • C 3 -C 7 cycloalkylene is selected from: 1,1 -cyclopropanediyl, 1,1 -cyclobutanediyl, 1,1 -cyclopentanediyl, 1,1- cyclohexanediyl, 1,1 -cycloheptanediyl, and the like.
  • C 3 -C 7 cycloalkylene is selected from: 1 ,2-cyclopropanediyl, 1 ,2 -cyclobutanediyl, 1 ,2-cyclopentanediyl, 1 ,2- cyclohexanediyl, 1 ,2-cycloheptanediyl, and the like.
  • carbo-Ci-C ⁇ -alkoxy is intended to mean a C]-C 6 alkyl ester of a carboxylic acid, wherein Ci-C 6 alkyl has the same definition as found herein. Examples include, but are not limited to, carbomethoxy [-C(O)OCH 3 ], carboethoxy, carbo-n-propoxy, carboisopropoxy, carbo-n-butoxy, carbo-s-butoxy, carbo-isobutoxy, carbo-/-butoxy, carbo-M-pentoxy, carbo- isopentoxy, carbo-/-pentoxy, carbo-neopentoxy, carbo- ⁇ -hexyloxy, and the like.
  • carboxy is intended to mean the group -CO 2 H; also referred to as a carboxylic acid group.
  • cyano is intended to mean the group -CN.
  • C 2 -Cg dialkylamino is intended to mean a radical comprising an amino group substituted with two of the same or different Ci-C 4 alkyl groups, wherein Ci-C 4 alkyl has the same definition as found herein. Some examples include, but are not limited to,
  • dimethylamino methylethylamino, diethylamino, methylpropylamino, methylisopropylamino, ethylpropylamino, ethylisopropylamino, dipropylamino, propylisopropylamino, and the like.
  • Some embodiments are C 2 -C 4 dialkylamino.
  • C 2 -C 8 dialkylsulfonamide is intended to mean is intended to mean one of the following groups shown below: alkyl
  • Q-C 6 haloalkoxy is intended to mean a radical comprising a Ci-C 6 haloalkyl group directly attached to an oxygen atom, wherein Ci -C 6 haloalkyl has the same definition as found herein. Examples include, but are not limited to, difluoromethoxy, trifluoromethoxy, 2,2,2-trifiuoroethoxy, pentafluoroethoxy, and the like.
  • Ci-C 6 haloalkyl is intended to mean a radical comprising a Ci-C 6 alkyl group substituted with one or more halogens, wherein Ci-C 6 alkyl has the same definition as found herein.
  • the Q-C 6 haloalkyl may be fully substituted in which case it can be represented by the formula C n L 2n+I , wherein L is a halogen and "n" is 1, 2, 3, 4, 5 or 6. When more than one halogen is present then they may be the same or different and selected from: fluorine, chlorine, bromine, and iodine. In some embodiments, haloalkyl contains 1 to 5 carbons.
  • haloalkyl contains 1 to 4 carbons. In some embodiments, haloalkyl contains 1 to 3 carbons. In some embodiments, haloalkyl contains 1 or 2 carbons. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl,
  • chlorodifluoromethyl 2,2,2-trifluoroethyl, pentafluoroethyl, and the like.
  • halogen is intended to mean to a fluoro, chloro, bromo or iodo group.
  • heteroaryl is intended to mean a ring system containing 5 to 14 ring atoms, that may contain a single ring, two fused rings or three fused rings, and wherein at least one ring is aromatic and at least one ring atom is a heteroatom selected from, for example: O, S and N, wherein N is optionally substituted with H, Q-C 4 acyl, C r C 4 alkyl, or oxide (i.e., together with an aromatic ring nitrogen form an N-oxide).
  • Some embodiments contain 5 to 6 ring atoms for example furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and the like.
  • Some embodiments contain 8 to 14 ring atoms for example quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, triazinyl, indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl.
  • heteroarylene is intended to mean is intended to mean an aromatic ring di- radical containing 5 to 14 ring atoms that may be a single ring, two fused rings or three fused rings, wherein at least one aromatic ring atom is a heteroatom selected from, for example: O, S, and N, wherein N is optionally substituted with H, C 1 -C 4 acyl, C 1 -C 4 alkyl, or oxide (i.e., together with an aromatic ring nitrogen form an N-oxide).
  • Some embodiments contain 5 to 6 ring atoms for example furandiyl, thiophenediyl, pyrrolediyl, imidazolediyl, oxazolediyl, thiazolediyl, isoxazolediyl, pyrazolediyl, isothiazolediyl, oxadiazolediyl, triazolediyl, thiadiazolediyl, pyridinediyl, pyrazinediyl, pyrimidinediyl, pyridazinediyl, triazinediyl, and the like.
  • Some embodiments contain 8 to 14 ring atoms for example quinolizinediyl, quinolinediyl, isoquinolinediyl, cinnolinediyl, phthalazinediyl, quinazolinediyl, quinoxalinediyl, triazinediyl, indolediyl, isoindolediyl, indazolediyl, indolizinediyl, purinediyl, naphthyridinediyl, pteridinediyl, carbazolediyl, acridinediyl.
  • quinolizinediyl for example quinolizinediyl, quinolinediyl, isoquinolinediyl, cinnolinediyl, phthalazinediyl, quinazolinediyl, quinoxalinediyl, triazinediyl,
  • phenazinediyl phenothiazinediyl, phenoxazinediyl, benzoxazolediyl, benzothiazolediyl, lH-benzimidazolediyl, imidazopyridinediyl,
  • heteroaryloxy is intended to mean a radical comprising a heteroaryl group, attached to an oxygen, wherein heteroaryl has the same definition as found herein.
  • heterobicyclyl is intended to mean a radical comprising two fused or bridged, non- aromatic rings containing 5 to 11 ring atoms wherein one, two, three or four ring atoms are heteroatoms selected from, for example: O, S, and ⁇ , wherein ⁇ is substituted with ⁇ , Cj-C 4 acyl or Cj-C 4 alkyl, and S is optionally substituted with one or two oxygens.
  • heterobicyclyl group include, but are not limited to, octahydropyrrolo[l,2-a]pyrazinyl, 1-aza- bicyclo[2.2.2]octyl, 9-aza-bicyclo[3.3. l]nonyl, and the like.
  • heterocyclyl is intended to mean a non-aromatic ring radical containing 3 to 8 ring atoms, wherein one, two or three ring atoms are heteroatoms selected from, for example: O, S, and ⁇ , wherein ⁇ is substituted with ⁇ , C r C 4 acyl or C 1 -C 4 alkyl, and S is optionally substituted with one or two oxygens.
  • heterocyclyl group examples include, but are not limited to, aziridinyl, azetidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, [1,3]- dioxolanyl, thiomorpholinyl, [l,4]oxazepanyl, 1,1-dioxothiomorpholinyl, azepanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, l-oxo-hexahydro-l ⁇ 4 -thiopyranyl, I,l-dioxo-hexahydro-l ⁇ 6 -thiopyranyl, and the like.
  • heterocyclylene is intended to mean a non-aromatic ring di-radical containing 3 to 8 ring atoms, wherein one, two or three ring atoms are heteroatoms selected from, for example: O, S, and ⁇ , wherein ⁇ is substituted with ⁇ , C 1 -C 4 acyl or C 1 -C 4 alkyl, and S is optionally substituted with one or two oxygens.
  • heterocyclylene group examples include, but are not limited to, aziridinediyl, azetidinediyl, piperidinediyl, morpholinediyl, piperazinediyl, pyrrolidinediyl, [l,3]-dioxolanediyl, thiomorpholinediyl, [l,4]oxazepanediyl, 1,1-dioxothiomorpholinediyl, azepanediyl, tetrahydrofurandiyl, and the like.
  • hydroxyl is intended to mean the group -OH.
  • phosphonooxy is intended to mean the group -OP(O)(OH) 2 .
  • ureyl is intended to mean the group -NH 2 C(O)NH 2 .
  • One aspect of the present invention pertains to certain compounds as shown in Formula Ia and pharmaceutically acceptable salts, solvates, and hydrates thereof:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, and Y have the same definitions as described herein, supra and infra.
  • substituted indicates that at least one hydrogen atom of the chemical group is replaced by a non-hydrogen substituent or group, the non-hydrogen substituent or group can be monovalent or divalent. When the substituent or group is divalent, then it is understood that this group is further substituted with another substituent or group.
  • a chemical group herein when a chemical group herein is "substituted" it may have up to the full valance of substitution; for example, a methyl group can be substituted by 1, 2, or 3 substituents, a methylene group can be substituted by 1 or 2 substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5 substituents, a naphthyl group can be substituted by 1, 2, 3, 4, 5, 6, or 7 substituents, and the like.
  • substituted with one or more substituents refers to the substitution of a group with one substituent up to the total number of substituents physically allowed by the group. Further, when a group is substituted with more than one group they can be identical or they can be different.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is understood that the various tautomeric forms are within the scope of the compounds of the present invention.
  • the present disclosure includes all isotopes of atoms occurring in the present compounds, salts and crystalline forms thereof.
  • Compounds of the invention can also include all isotopes of atoms occurring in the intermediates and/or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include 2 H (deuterium) and 3 H (tritium).
  • Isotopes of carbon include 13 C and 14 C. It is understood and appreciated that compounds of Formula Ia and formulae related thereto may have one or more chiral centers and therefore can exist as enantiomers and/or diastereoisomers.
  • R 1 is selected from: H and Q-C 6 alkyl.
  • R 1 is H.
  • R 1 is C 1 -C 6 alkyl.
  • R 1 is methyl
  • R 1 is isopropyl
  • R 2 is selected from: H and Q-C 6 alkyl.
  • R 2 is H.
  • R 2 is C 1 -C 6 alkyl.
  • R 2 is methyl
  • R 2 is isopropyl
  • R 3 is selected from: H and C 1 -C 6 alkyl. In some embodiments, R 3 is H.
  • R 3 is Ci-C 6 alkyl.
  • R 3 is methyl
  • R 3 is isopropyl.
  • R 4 is selected from: H and Ci-C 6 alkyl. In some embodiments, R 4 is H.
  • R 4 is Ci-C 6 alkyl.
  • R 4 is methyl
  • R 4 is isopropyl.
  • R 5 is selected from: H and C]-C 6 alkyl. In some embodiments, R 5 is H.
  • R 5 is Q-C 6 alkyl.
  • R 5 is methyl
  • R 5 is isopropyl.
  • the Group R 6 is isopropyl.
  • R 6 is selected from: H and Cj-C 6 alkyl.
  • R 6 is H.
  • R 6 is Ci-C 6 alkyl.
  • R 6 is methyl
  • R 6 is isopropyl.
  • X is NR 7 ; wherein R 7 is -R 10 -R ⁇ -R 12 -R 13 In some embodiments, X is CCONR 8 R 9 .
  • X is CC(O)NHR 8 .
  • Y is NR 7 ; wherein R 7 is -R 10 -R n -R 12 -R 13 In some embodiments, Y is CCONR 8 R 9 .
  • Y is CC(O)NHR 8 .
  • R 7 is -R I0 -R ⁇ -R I2 -R u , or an N-oxide thereof.
  • R 7 is -R 10 -R ⁇ -R 12 -R 13 .
  • R 7 is selected from: aryl and heteroaryl; wherein said aryl and heteroaryl are each optionally substituted with one or two substituents selected from: cyano and halogen.
  • R 7 is selected from: aryl and heteroaryl; wherein said aryl and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, chloro, and cyano.
  • R 7 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 5- chloro-pyridin-2-yl, 5-cyano-pyrazin-2-yl, pyrazin-2-yl, 5-fluoro-pyridin-2-yl, 4-chloro-pyridin- 2-yl, 4-fluoro-pyridin-2-yl, 4-cyano-pyridin-2-yl, and 4-oxy-pyrazin-2-yl.
  • R 7 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 5- chloro-pyridin-2-yl, 5-cyano-pyrazin-2-yl, pyrazin-2-yl, 5-fluoro-pyridin-2-yl, 4-chloro-pyridin- 2-yl, 4-fluoro-pyridin-2-yl, 4-cyano-pyridin-2-yl, and 4-oxy-pyrazin-2-yl.
  • R 7 is selected from: 2,4-difluoro-phenyl, 5-bromo-pyridin-2-yl,
  • R 7 is selected from: 2,4-difluoro-phenyl, 5-bromo-pyridin-2-yl, 4-cyano-phenyl, pyridin-3-yl, pyridin-2-yl, 5-thiazol-2-yl-pyridin-2-yl, 5-trifluoromethyl- pyridin-2-yl, 5- ⁇ -tolyl-pyridin-2-yl, 5-dimethylamino-pyrazin-2-yl, 2,4-dichloro-phenyl, 5- isopropyl-pyridin-2-yl, 5-methyl-pyridin-2-yl, 5-(4-methoxy-phenyl)-pyridin-2-yl, 2-fluoro-4- methanesulfonyl-phenyl, 2-fluoro-phenyl, 5-chloro-pyridin-2-yl, 5-bromo-pyridin-3-yl, tert- butyl, 2-methoxy-pyr
  • R 7 is 2,4-difluoro-phenyl. In some embodiments, R 7 is 5-bromo- pyridin-2-yl. In some embodiments, R 7 is 4-cyano-phenyl. In some embodiments, R 7 is pyridin- 3-yl. In some embodiments, R 7 is pyridin-2-yl. In some embodiments, R 7 is 5-thiazol-2-yl- pyridin-2-yl. In some embodiments, R 7 is 5-trifluoromethyl-pyridin-2-yl. In some embodiments, R 7 is 5- ⁇ -tolyl-pyridin-2-yl. In some embodiments, R 7 is 5-dimethylamino-pyrazin-2-yl.
  • R 7 is 2,4-dichloro-phenyl. In some embodiments, R 7 is 5-isopropyl-pyridin-2-yl. In some embodiments, R 7 is 5-methyl-pyridin-2-yl. In some embodiments, R 7 is 5-(4-methoxy- phenyl)-pyridin-2-yl. In some embodiments, R 7 is 2-fluoro-4-methanesulfonyl-phenyl. In some embodiments, R 7 is 2-fluoro-phenyl. In some embodiments, R 7 is 5-chloro-pyridin-2-yl. In some embodiments, R 7 is 5-bromo-pyridin-3-yl.
  • R 7 is tert-butyl. In some embodiments, R 7 is 2-methoxy-pyridin-4-yl. In some embodiments, R 7 is 2,2-dimethyl-propyl. In some embodiments, R 7 is tetrahydro-pyran-4-ylmethyl. In some embodiments, R 7 is phenyl. In some embodiments, R 7 is 4-trifluoromethyl-pyridin-2-yl. In some embodiments, R 7 is 6- chloro-pyrazin-2-yl. In some embodiments, R 7 is l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl.
  • R 7 is 5-morpholin-4-yl-pyridin-2-yl. In some embodiments, R 7 is 6-bromo- pyridin-3-yl. In some embodiments, R 7 is 5-methoxy-pyridin-2-yl. In some embodiments, R 7 is 5,6-difluoro-pyridin-3-yl. In some embodiments, R 7 is 6-methoxy-pyridazin-3-yl. In some embodiments, R 7 is 2-chloro-pyridin-4-yl. In some embodiments, R 7 is S-cyclopropyl-pyrazin- ⁇ - yl.
  • R 7 is l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 7 is l-benzyl-piperidin-4-yl. In some embodiments, R 7 is 6-cyano-pyrazin-2-yl. In some embodiments, R 7 is 2-hydroxy-2-methyl-propyl. In some embodiments, R 7 is 4-fluoro-phenyl. In some embodiments, R 7 is 5-ethyl-pyridin-2-yl. In some embodiments, R 7 is isopropyl. In some embodiments, R 7 is 5-phenyl-pyridin-2-yl. In some embodiments, R 7 is pyridin-4-yl.
  • R 7 is 2,5-difluoro-phenyl. In some embodiments, R 7 is 3-fluoro-phenyl. In some embodiments, R 7 is pyrimidin-4-yl. In some embodiments, R 7 is 2-(tetrahydro-pyran-4-yl)-ethyl. In some embodiments, R 7 is 3,5-difluoro-pyridin-2-yl. In some embodiments, R 7 is pyrazin-2-yl. In some embodiments, R 7 is tetrahydro-thiopyran-4-yl. In some embodiments, R 7 is 5-p-tolyl- pyridin-2-yl. In some embodiments, R 7 is 4-methoxy-phenyl.
  • R 7 is 2- morpholin-4-yl-ethyl. In some embodiments, R 7 is 5-cyano-pyridin-2-yl. In some embodiments, R 7 is 5-cyano-pyrazin-2-yl. In some embodiments, R 7 is 6'-methyl-[3,3']bipyridinyl-6-yl. In some embodiments, R 7 is 6-chloro-pyridazin-3-yl. In some embodiments, R 7 is 5-fluoro-pyridin- 2-yl. In some embodiments, R 7 is 5-ethyl-pyrazin-2-yl. In some embodiments, R 7 is 6-methoxy- pyrazin-2-yl.
  • R 7 is 5-dimethylamino-pyridin-2-yl. In some embodiments, R 7 is 1 -(4-fluoro-phenyl)- 1 -methyl-ethyl. In some embodiments, R 7 is 5-pyrimidin-5-yl-pyridin- 2-yl. In some embodiments, R 7 is 4-methyl -pyridin-2-yl. In some embodiments, R 7 is 5- methoxy-pyrazin-2-yl. In some embodiments, R 7 is 5-propyl-pyridin-2-yl. In some embodiments,
  • R 7 is 5-/w-tolyl-pyridin-2-yl. In some embodiments, R 7 is 5-hydroxy-pyrazin-2-yl. In some embodiments, R 7 is cyclopropyl-pyridin-2-yl. In some embodiments, R 7 is 2,6-difluoro- phenyl. In some embodiments, R 7 is 3-fluoro-pyridin-4-yl. In some embodiments, R 7 is 5- isopropyl-pyrazin-2-yl. In some embodiments, R 7 is 5-bromo-pyrazin-2-yl. In some embodiments,
  • R 7 is 5-cyclopentyl-pyridin-2-yl. In some embodiments, R 7 is ⁇ -tolyl. In some embodiments, R 7 is 4-fluoro-benzyl. In some embodiments, R 7 is 3-methyl-pyridin-2-yl. In some embodiments, R 7 is 6-methyl-4-trifluoromethyl-pyridin-2-yl. In some embodiments, R 7 is 6-dimethylamino-pyrazin-2-yl. In some embodiments, R 7 is I,l-dioxo-hexahydro-l ⁇ 6 -thiopyran- 4-yl. In some embodiments, R 7 is 5-(4-fluoro-phenyl)-pyridin-2-yl.
  • R 7 is 5-cyclopropyl-pyridin-2-yl. In some embodiments, R 7 is 6-ethyl-pyrazin-2-yl. In some embodiments, R 7 is 5-methylamino-pyrazin-2-yl. In some embodiments, R 7 is dichloro-phenyl. Li some embodiments, R 7 is 5-methyl-pyrazin-2-yl. In some embodiments, R 7 is 3-fluoro- pyridin-2-yl. In some embodiments, R 7 is 5-cyclobutyl-pyrazin-2-yl. In some embodiments, R 7 is 5-ethoxy-pyrazin-2-yl. In some embodiments, R 7 is 5-trifluoromethyl-pyrazin-2-yl.
  • R 7 is 5-cyano-pyridin-3-yl. In some embodiments, R 7 is 5-cyclopropylmethyl- pyrazin-2-yl. In some embodiments, R 7 is 5-pentafluoroethyl-pyrazin-2-yl. In some
  • R 7 is 5-heptafluoropropyl-pyrazin-2-yl. In some embodiments, R 7 is 5-chloro-4- methyl-pyridin-2-yl. In some embodiments, R 7 is 5-chloro-4-trifluoromethyl-pyridin-2-yl. In some embodiments, R 7 is 4-bromo-pyridin-2-yl. In some embodiments, R 7 is 4-chloro-pyridin- 2-yl. In some embodiments, R 7 is 4-fluoro-pyridin-2-yl. In some embodiments, R 7 is 4-oxy- pyrazin-2-yl. In some embodiments, R 7 is 4-cyclopropyl-pyridin-2-yl.
  • R 7 is 4-cyano-pyridin-2-yl. In some embodiments, R 7 is 4-methanesulfonyl-pyridin-2-yl. In some embodiments, R 7 is 4-methoxy-pyridin-2-yl. In some embodiments, R 7 is piperidin-4-yl. In some embodiments, R 7 is tetrahydro-pyran-4-yl. In some embodiments, R 7 is 3-methyl-l,l- dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 7 is 5-chloro-3-fluoro-pyridin-2-yl.
  • R 7 is 3-fluoro-5-methoxy-pyridin-2-yl. In some embodiments, R 7 is 2- chloro-4-fluoro-phenyl. In some embodiments, R 7 is 6-fluoro-pyridin-3-yl. In some
  • R 7 is 6-cyano-pyridin-3-yl. In some embodiments, R 7 is 3-hydroxy-3-methyl- butyl. In some embodiments, R 7 is 4-iodo-pyridin-2-yl. In some embodiments, R 7 is 1-oxy- pyridin-3-yl. In some embodiments, R 7 is 4-tert-butylcarbamoyl-pyridin-2-yl. In some embodiments, R 7 is 4-hydroxy-pyridin-2-yl.
  • R 8 is -R 14 -R 15 -R 16 -R 17 .
  • R 8 is selected from: l-hydroxymethyl-2,2-dimethyl -propyl, 2- hydroxy- 1,1 -dimethyl -ethyl, 1 -hydroxymethyl-cyclopropyl, 2-hydroxy-indan-l-yl, 1- hydroxymethyl-cyclobutyl, tert-buty ⁇ , 2-hydroxy-l -phenyl -ethyl, 2-hydroxy-l -hydroxymethyl- 1 -methyl -ethyl, tert-butylamino, 2,2,2-trifluoro-l,l-dimethyl-ethyl, 2-methyl-l- (phosphonooxy)propan-2-yl, 1 -methyl-cyclobutyl, 1-hydroxymethyl -2 -methyl -propyl, cyano- dimethyl-methyl, 2,2-dimethyl-l-(methylcarbamoyl)-propyl, 3,3-dimethyl-l- (phosphonooxy)butan-2-yl, 2-hydroxy-l
  • R 8 is selected from: H, 2-methyl-2-morpholin-4-yl-propyl, 1- hydroxymethyl-2,2-dimethyl-propyl, 2-(tert-butoxycarbonylamino)cyclohexyl, 1 -phenyl- cyclopropyl, 5-trifluoromethyl-pyridin-2-yl, 1 -methyl- 1 -phenyl -ethyl, 1 -(2-methoxy-ethyl)- pyrrolidin-3-ylmethyl, 1 -(methoxycarbonytycyclopropyl, tetrahydro-pyran-4-ylmethyl,
  • R 8 is selected from: H, 2-methyl-2-morpholin-4-yl-propyl, 1- hydroxymethyl-2,2-dimethyl -propyl, 2-(tert-butoxycarbonylamino)cyclohexyl, 1 -phenyl- cyclopropyl, 5-trifluoromethyl-pyridin-2-yl, 1 -methyl- 1 -phenyl -ethyl, 1 -(2-methoxy-ethyl)- pyrrolidin-3-ylmethyl, 1 -(methoxycarbonyl)cyclopropyl, tetrahydro-pyran-4-ylmethyl,
  • R 8 is ⁇ . In some embodiments, R 8 is 2-methyl-2-morpholin-4-yl- propyl. In some embodiments, R 8 is l-hydroxymethyl-2,2-dimethyl-propyl. In some
  • R 8 is 2-(tert-butoxycarbonylamino)cyclohexyl. In some embodiments, R 8 is 1- phenyl-cyclopropyl. In some embodiments, R 8 is 5-trifluoromethyl-pyridin-2-yl. In some embodiments, R 8 is 1 -methyl- 1-phenyl-ethyl. In some embodiments, R 8 is l-(2-methoxy-ethyl)- pyrrolidin-3-ylmethyl. In some embodiments, R 8 is l-(methoxycarbonyl)cyclopropyl. In some embodiments, R 8 is tetrahydro-pyran-4-ylmethyl. In some embodiments, R 8 is
  • R 8 is 1 -(4-fluoro-phenyl)- cyclopropyl. In some embodiments, R 8 is 6-methyl-pyridin-3-ylmethyl. In some embodiments, R 8 is 2-hydroxy- 1-phenyl-ethyl. In some embodiments, R 8 is l,3,3-trimethyl-bicyclo[2.2.1]hept- 2-yl. In some embodiments, R 8 is 2-hydroxy-l,l -dimethyl -ethyl. In some embodiments, R 8 is 2- (5-hydroxy-lH-indol-3-yl)-ethyl.
  • R 8 is 1-hydroxymethyl-cyclopropyl. In some embodiments, R 8 is 3-chloro-5-methyl-pyridin-2-yl. In some embodiments, R 8 is 6-fluoro- pyridin-3-yl. In some embodiments, R 8 is l-(3-fluoro-phenyl)-cyclobutyl. In some
  • R 8 is 2-methyl-pyridin-3-yl. In some embodiments, R 8 is 2-hydroxy-l-
  • R 8 is 2-(pyridin-3-yloxy)-propyl.
  • R 8 is carbamoyl-phenyl-methyl.
  • R 8 is 5-fluoro-2-methoxy- phenyl.
  • R 8 is 2-methoxy-ethyl.
  • R 8 is 2,3- dihydroxy-propyl.
  • R 8 is l-(tert-butoxycarbonyl)pyrrolidin-3-yl.
  • R 8 is 2-oxo-2-phenyl-ethyl.
  • R 8 is l-(3,3,3-trifluoro- propyl)-azetidin-3-yl. In some embodiments, R 8 is 2-hydroxy-l-pyridin-2-yl-ethyl. In some embodiments, R 8 is 3-hydroxy-pyridin-4-yl. In some embodiments, R 8 is 1 -methyl- l-pyridin-4- yl-ethyl. In some embodiments, R 8 is l-hydroxymethyl-2-3H-imidazol-4-yl-ethyl. In some embodiments, R 8 is 4-hydroxy-3-methoxy-benzyl.
  • R 8 is 5-fluoro-2-oxo- 2,3-dihydro-pyrimidin-4-yl. In some embodiments, R 8 is l-(4-fluoro-phenyl)-3 -hydroxy-propyl. In some embodiments, R 8 is l-pyridin-4-yl-cyclopropyl. In some embodiments, R 8 is 2-hydroxy-l-pyridin-3-yl-ethyl. In some embodiments, R 8 is 1,1-dimethyl- 2-(4-methyl-piperidin-l-yl)-ethyl. In some embodiments, R 8 is 6-cyano-pyridin-3-yl.
  • R 8 is 5-fluoro-pyridin-2-yl. In some embodiments, R 8 is 2,5-dimethyl-benzyl. In some embodiments, R 8 is l-isopropyl-piperidin-4-yl. In some embodiments, R 8 is 2-methoxy-l- methoxymethyl-ethyl. In some embodiments, R 8 is 2,3-dimethyl-benzyl. In some embodiments, R 8 is l-pyridin-2-yl-ethyl. In some embodiments, R 8 is 6-chloro-pyridin-3-ylmethyl. In some embodiments, R 8 is 3-methyl-pyridin-2-yl.
  • R 8 is 2-hydroxy-indan-l-yl. In some embodiments, R 8 is (l.S',25)-2-hydroxy-mdan-l-yl. In some embodiments, R 8 is (lS,2i?)- 2-hydroxy-indan-l-yl. In some embodiments, R 8 is (li?,2i?)-2-hydroxy-indan-l-yl. In some embodiments, R 8 is (l/?,25)-2-hydroxy-mdan-l-yl. In some embodiments, R 8 is 1- hydroxymethyl-cyclobutyl. In some embodiments, R 8 is 2-(4-chloro-phenyl)-l,l-dimethyl-ethyl.
  • R 8 is 3-hydroxy-pyridm-2-ylmethyl. In some embodiments, R 8 is 3- methyl-pyridin-4-yl. In some embodiments, R 8 is 5-tert-butyl-isoxazol-3-yl. In some embodiments, R 8 is l-(6-methoxy-pyridin-3-yl)-l-methyl-ethyl. In some embodiments, R 8 is lH-benzoimidazol-2-yl. In some embodiments, R 8 is tert-buty ⁇ . In some embodiments, R 8 is 4- phenyl-thiazol-2-yl. In some embodiments, R 8 is l-(2-fluoro-phenyl)-cyclobutyl.
  • R 8 is 2,4-dimethoxy-benzyl. In some embodiments, R 8 is 5-bromo-3-methyl- pyridin-2-yl. In some embodiments, R 8 is 4-benzyl-morpholin-2-ylmethyl. In some
  • R 8 is 6-trifluoromethyl-pyridin-3-ylmethyl. In some embodiments, R 8 is tetrahydro-furan-3-yl. In some embodiments, R 8 is pyridin-3-ylmethyl. In some embodiments, R 8 is pyrazin-2-yl. In some embodiments, R 8 is piperidin-4-yl. In some embodiments, R 8 is l-(6- hydroxy-pyridin-3-yl)-l -methyl-ethyl. In some embodiments, R 8 is 1 -methyl- l-pyridin-2-yl- ethyl. In some embodiments, R 8 is 1-hydroxymethyl-cyclopentyl.
  • R 8 is 1- aza-bicyclo[2.2.2]oct-3-yl. In some embodiments, R 8 is 2-hydroxy-cyclopentyl. In some embodiments, R 8 is 2-hydroxy-l-(hydroxymethyl)-propyl. In some embodiments, R 8 is ⁇ - ⁇ tert- butoxycarbonyl)piperidin-4-yl)methyl. In some embodiments, R 8 is 3,5-dimethoxy-phenyl. In some embodiments, R 8 is 6-fluoro-4H-benzo[l,3]dioxin-8-ylmethyl. In some embodiments, R 8 is 4,6-dimethyl-pyridin-2-yl.
  • R 8 is l,l-dimethyl-2-morpholin-4-yl-ethyl. In some embodiments, R 8 is 2-hydroxy-cyclohexylmethyl. In some embodiments, R 8 is l-(4- methoxy-phenyl)-cyclopropyl. In some embodiments, R 8 is l-ethyl-pyrrolidin-2-ylmethyl. In some embodiments, R 8 is indan-1-yl. In some embodiments, R 8 is pyrimidin-4-yl. In some embodiments, R 8 is 2-fluoro-4-methanesulfbnyl-phenyl. In some embodiments, R 8 is 6-hydroxy- pyridin-2-yl.
  • R 8 is cyclobutyl. In some embodiments, R 8 is l-(3- methoxy-phenyl)-cyclopropyl. In some embodiments, R 8 is l-(3,3,3-trifluoro-propyl)- pyrrolidin-3-yl. In some embodiments, R 8 is 2-hydroxy-pyridin-3-yl. In some embodiments, R 8 is 4-difluoromethoxy-benzyl. In some embodiments, R 8 is 1-piperidin-l-yl-cyclopentylmethyl. In some embodiments, R 8 is 3 -hydroxy-3 -methyl -butyl.
  • R 8 is l-(4-fluoro- phenyl)-cyclobutyl. In some embodiments, R 8 is 4-methoxy-benzyl. In some embodiments, R 8 is pyridin-2-yl. In some embodiments, R 8 is 2-hydroxy-2-phenyl-ethyl. In some embodiments, R 8 is 2-hydroxymethyl-2,3-dihydro-indol-l-yl. In some embodiments, R 8 is 3-hydroxy-pyridin-2- yl. In some embodiments, R 8 is 4-dimethylamino-tetrahydro-pyran-4-ylmethyl. In some embodiments, R 8 is 2-(4-fluoro-phenyl)-ethyl. In some embodiments, R 8 is l-(2-methoxy-ethyl)- piperidin-4-ylmethyl. In some embodiments, R 8 is 2-morpholin-4-yl-ethyl. In some embodiments,
  • R 8 is l-(/ert-butoxycarbonyl)-4-carboxypiperidm-4-yl. In some embodiments, R 8 is quinolin-3-yl. In some embodiments, R 8 is l-morpholin-4-ylmethyl-cyclopentyl. In some embodiments, R 8 is l,4-dimethyl-lH-pyrrol-2-ylmethyl. In some embodiments, R 8 is 2-hydroxy- 2-pyridin-2-yl-ethyl. In some embodiments, R 8 is pyridin-3-yl. In some embodiments, R 8 is 2- dimethylamino-benzyl. In some embodiments, R 8 is tetrahydro-thiopyran-4-yl.
  • R 8 is 1-m-tolyl-cyclopropyl. In some embodiments, R 8 is l-(2-methoxy-ethyl)- piperidin-3-yl. In some embodiments, R 8 is 5-methoxy-pyridin-2-ylmethyl. In some
  • R 8 is 2-hydroxy-l-pyridin-4-yl-ethyl. In some embodiments, R 8 is 4-methyl- pyridin-2-yl. In some embodiments, R 8 is 4-carboxy-2-fluorophenyl. In some embodiments, R 8 is 6-methanesulfonyl-pyridin-3-yl. In some embodiments, R 8 is 1-o-tolyl-cyclobutyl. In some embodiments, R 8 is l,l-dimethyl-2-pyrrolidin-l-yl-ethyl. In some embodiments, R 8 is 2,6- dimethoxy-pyridin-3-yl. In some embodiments, R 8 is pyridin-2-yl.
  • R 8 is 4-hydroxymethyl-tetrahydro-pyran-4-yl. In some embodiments, R 8 is 2-(lH-imidazol-4-yl)- ethyl. In some embodiments, R 8 is 3-fluoro-pyridin-4-yl. In some embodiments, R 8 is 1- carbamoyl-2-phenyl-ethyl. In some embodiments, R 8 is oxazol-4-ylmethyl. In some
  • R 8 is 6-methoxy-pyrimidin-4-yl. In some embodiments, R 8 is 1,1-dioxo- hexahydro-l ⁇ 6 -thiopyran-4-yl. In some embodiments, R 8 is l-methoxy-l-oxo-3-phenylpropan- 2-yl. In some embodiments, R 8 is l-(2-methoxy-ethyl)-pyrrolidin-3-yl. In some embodiments, R 8 is l-(6-methyl-pyridin-2-yl)-ethyl. In some embodiments, R 8 is 2 -hydroxy- l-(4-hydroxy- phenyl)-ethyl.
  • R 8 is 2-methoxy-pyridin-4-yl. In some embodiments, R 8 is l-pyridin-2-yl-cyclopropyl. In some embodiments, R 8 is l-(tert-butoxycarbonyl)piperidin-3-yl. In some embodiments, R 8 is 3-methyl-pyridin-2-ylmethyl. In some embodiments, R 8 is 3-fluoro- pyridin-2-yl. In some embodiments, R 8 is l-pyridin-4-yl-cyclobutyl. In some embodiments, R 8 is 2-carboxy-l-(pyridin-3-yl)ethyl. In some embodiments, R 8 is 2-hydroxy-l -methyl-ethyl.
  • R 8 is l-(methoxycarbonyl)cyclohexyl. In some embodiments, R 8 is 3- hydroxymethyl-pyridin-4-yl. In some embodiments, R 8 is 2-hydroxy-l-phenyl-ethyl. In some embodiments, R 8 is S-dimethylamino-tetrahydro-thiophen-B-ylmethyl. In some embodiments, R 8 is tetrahydro-pyran-4-yl. In some embodiments, R 8 is 5-chloro-pyridin-2-yl. In some embodiments,
  • R 8 is 1-carbamoyl-cyclobutyl. In some embodiments, R 8 is 5-fluoro-2-methyl- benzyl. In some embodiments, R 8 is 2-morpholin-4-yl-2-pyridin-3-yl-ethyl. In some
  • R 8 is l-(3-methoxy-phenyl)-cyclobutyl. In some embodiments, R 8 is 5-methyl- pyridin-2-yl. In some embodiments, R 8 is l-(tetrahydro-fiiran-2-yl)methyl. In some
  • R 8 is l-dimethylaminomethyl-cyclopentyl. In some embodiments, R 8 is 2-(4- fluoro-phenyl)-l-methyl-ethyl. In some embodiments, R 8 is benzothiazol-2-yl. In some embodiments, R 8 is l-(2-fluoro-phenyl)-cyclopropyl. In some embodiments, R 8 is l-(2- methoxy-ethyl)-piperidin-4-yl. In some embodiments, R 8 is 2-hydroxy-l -pyridin-4-yl-ethyl.
  • R 8 is l-(3,3,3-trifluoro-propyl)-azetidin-3-ylmethyl. In some embodiments, R 8 is ⁇ -pyrrolidin-l-yl-pyridin ⁇ -ylmethyl. In some embodiments, R 8 is 1,1-dioxo-tetrahydro- l ⁇ 6 -thiophen-3-yl. In some embodiments, R 8 is 2,3-dimethoxy-benzyl. In some embodiments, R 8 is 3-cyano-5-methyl-pyridin-2-yl. In some embodiments, R 8 is 2,3-dihydro-benzofuran-3-yl. In some embodiments, R 8 is 1-hydroxymethyl-cyclohexyl.
  • R 8 is 2,5- difluoro-benzyl. In some embodiments, R 8 is 4-dimethylamino-benzyl. In some embodiments, R 8 is 4-hydroxy-l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 8 is 4- trifluoromethyl-pyridin-2-yl. In some embodiments, R 8 is 5-methyl-thiazol-2-yl. In some embodiments, R 8 is 6-trifluoromethyl-pyridin-3-yl. In some embodiments, R 8 is 5-hydroxy-lH- pyrazol-3-yl. In some embodiments, R 8 is 2-thiomorpholin-4-yl-ethyl.
  • R 8 is benzo[l,3]dioxol-5-ylmethyl.
  • R 8 is 2-amino-cyclohexyl.
  • R 8 is 3-dimethylamino-l-oxo-tetrahydro-l ⁇ 4 -thiophen-3-ylmethyl.
  • R 8 is 4-methyl-morpholin-2-ylmethyl.
  • R 8 is l-(2-methoxy- phenyl)-cyclopropyl.
  • R 8 is 2-carboxy-l-(4-fluorophenyl)propan-2-yl.
  • R 8 is pyridin-2-ylmethyl.
  • R 8 is pyridazin-3-yl. In some embodiments, R 8 is 4-pyridin-2-yl-thiazol-2-yl. In some embodiments, R 8 is 1 -(3,3,3- trifluoro-propyl)-piperidin-4-ylmethyl. In some embodiments, R 8 is 6-chloro-2-methyl-pyridin- 3-yl. In some embodiments, R 8 is 6-hydroxy-pyridin-3-yl. In some embodiments, R 8 is 3- trifluoromethoxy-benzyl. In some embodiments, R 8 is l-morpholin-4-yl-cyclopentylmethyl.
  • R 8 is l-pyridin-2-yl-cyclobutylmethyl. In some embodiments, R 8 is 2- hydroxy-1-hydroxymethyl-l-methyl-ethyl. In some embodiments, R 8 is 5-hydroxymethyl- pyridin-2-yl. In some embodiments, R 8 is 5-fluoro-l-oxy-pyridin-2-yl. In some embodiments, R 8 is 6-methoxy-pyridin-2-yl. In some embodiments, R 8 is l-methyl-l-pyridin-3-yl-ethyl. In some embodiments, R 8 is 6-methyl-pyridin-3-yl. In some embodiments, R 8 is 2-hydroxy-l- hydroxymethyl-propyl. In some embodiments, R 8 is 2-chloro-pyridin-3-yl. In some
  • R 8 is 3-methyl-3H-imidazol-4-ylmethyl. In some embodiments, R 8 is 6-fluoro- pyridin-2-yl. In some embodiments, R 8 is 3-dimethylamino-benzyl. In some embodiments, R 8 is 6-morpholin-4-yl-pyridin-3-yl. In some embodiments, R 8 is 1-o-tolyl-cyclopropyl. In some embodiments, R 8 is l-(3,3,3-trifluoro-propyl)-piperidin-3-yl. In some embodiments, R 8 is 6- methanesulfonyl-4-methyl-pyridin-3-yl. In some embodiments, R 8 is 2-methyl-quinolin-4-yl. In some embodiments, R 8 is l-(3,3,3-trifluoro-propyl)-pyrrolidin-3-ylmethyl. In some embodiments,
  • R 8 is benzooxazol-2-yl. In some embodiments, R 8 is 1 -methyl -piperidin-4- ylmethyl. In some embodiments, R 8 is 2-(2,6-dimethyl-mo ⁇ holin-4-yl)-2-methyl-propyl. In some embodiments, R 8 is 1 -methyl -piperidin-2 -ylmethyl. In some embodiments, R 8 is pyridin-4- ylmethyl. In some embodiments, R 8 is 4-hydroxymethyl-pyridin-2-yl. In some embodiments, R 8 is 5,7-dimethyl-pyrazolo[l,5-a]pyrimidin-2-yl.
  • R 8 is 6,6-dimethyl- bicyclo[3.1.1]hept-2-ylmethyl. In some embodiments, R 8 is l-(5-methyl-pyridin-2-yl)-ethyl. In some embodiments, R 8 is 2-fluoro-pyridin-3-yl. In some embodiments, R 8 is morpholin-4-yl. In some embodiments, R 8 is 2-hydroxy-2-pyridin-4-yl-ethyl. In some embodiments, R 8 is pyridin- 4-yl. In some embodiments, R 8 is 4-hydroxy-pyridin-2-yl. In some embodiments, R 8 is 3- methoxy-benzyl.
  • R 8 is l-oxy-pyridin-2-yl. In some embodiments, R 8 is 1-ethyl-propyl. In some embodiments, R 8 is 6-carboxypyridin-2-yl. In some embodiments, R 8 is l,2,2,6,6-pentamethyl-piperidin-4-yl. In some embodiments, R 8 is 6-methoxy-pyridin-3-yl. In some embodiments, R 8 is cyclopentyl. In some embodiments, R 8 is morpholin-2 -ylmethyl. In some embodiments, R 8 is l-(tert-butoxycarbonyl)azetidin-3-yl)methyl.
  • R 8 is 2-dimethylamino-2-pyridin-3-yl-ethyl. In some embodiments, R 8 is 1 -(4-methoxy-phenyl)- cyclobutyl. In some embodiments, R 8 is 3-hydroxy-benzyl. In some embodiments, R 8 is tetrahydro-furan-2 -ylmethyl. In some embodiments, R 8 is 4-(tert-butoxycarbonyl)morpholin-2- ylmethyl. In some embodiments, R 8 is l-(3-fluoro-phenyl)-cyclopropyl. In some embodiments, R 8 is 2-o-tolyl-ethyl.
  • R 8 is 3-hydroxymethyl-l-isobutyl-pyrrolidin-3-yl. In some embodiments, R 8 is l-(2-methoxy-ethyl)-azetidin-3-yl. In some embodiments, R 8 is 6- morpholin-4-yl-pyridin-2-ylmethyl. In some embodiments, R 8 is 1,1-dioxo-tetrahydro-l ⁇ 6 - thiophen-3 -ylmethyl. In some embodiments, R 8 is 2-(4-fluoro-phenoxy)-ethyl. In some embodiments, R 8 is 2,6-dimethyl-pyrimidin-4-yl.
  • R 8 is 1 -hydroxymethyl- 2-(3H-imidazol-4-yl)-ethyl. In some embodiments, R 8 is 4-methanesulfonyl-benzyl. In some embodiments, R 8 is l-pyridin-3-yl-cyclopropyl. In some embodiments, R 8 is 9-methyl-9-aza- bicyclo[3.3.1]non-l-yl. In some embodiments, R 8 is 2,6-dimethyl-pyridin-3-yl. In some embodiments, R 8 is 4-hydroxy-benzyl. In some embodiments, R 8 is 2-oxo-2-phenyl-ethyl).
  • R 8 is l-methyl-lH-pyrazol-3-ylmethyl. In some embodiments, R 8 is pyrimidin-2-yl. In some embodiments, R 8 is 5-methyl-pyrazin-2-yl. In some embodiments, R 8 is l-(2-methoxy-pyridin-3-yl)-l-methyl-ethyl. In some embodiments, R 8 is 6-methanesulfonyl-2- methyl-pyridin-3-yl. In some embodiments, R 8 is 2-hydroxy-benzyl. In some embodiments, R 8 is 6-bromo-2-methyl-pyridin-3-yl. In some embodiments, R 8 is 2-methoxy-pyridin-3-yl.
  • R 8 is l-(4-chloro-phenyl)-cyclobutyl. In some embodiments, R 8 is 2-(pyridine-2- sulfonyl)-ethyl. In some embodiments, R 8 is l-pyridin-2-yl-cyclopropylmethyl. In some embodiments, R 8 is l-methyl-l,2,3,4-tetrahydro-quinolin-7-yl. In some embodiments, R 8 is ben2yl. In some embodiments, R 8 is 3,5-dimethyl-pyrazin-2-yl. In some embodiments, R 8 is 1- (2-hydroxy-pyridin-3-yl)-l-methyl-ethyl.
  • R 8 is 1- (ethoxycarbonyl)cyclobutyl. In some embodiments, R 8 is l-(tert-butoxycarbonyl)pyrrolidin-3- ylmethyl. In some embodiments, R 8 is quinolin-4-ylmethyl. In some embodiments, R 8 is 2-(4- fluoro-phenyl)-l -(2 -hydroxy-ethylcarbamoyl)-l -methyl-ethyl. In some embodiments, R 8 is 2- morpholin-4-yl-pyridin-3-yl. In some embodiments, R 8 is 6-methyl-pyridin-2-yl. In some embodiments, R 8 is 3-difluoromethoxy-benzyl.
  • R 8 is 4-hydroxy-l- methyl-piperidin-4-ylmethyl. In some embodiments, R 8 is l-(2,5-dimethylpyrrolidine-l- carbonyl)cyclopentyl. In some embodiments, R 8 is 2-methoxy-benzyl. In some embodiments, R 8 is 6-methyl-pyridin-2 -ylmethyl. In some embodiments, R 8 is 3-chloro-pyridin-4-yl. In some embodiments, R 8 is 2-carboxypropan-2-yl. In some embodiments, R 8 is 6-chloro-pyridin-3-yl. In some embodiments, R 8 is 2-hydroxy-2-pyridin-3-yl-ethyl.
  • R 8 is 1-p-tolyl- cyclopropyl. In some embodiments, R 8 is l-(3,3,3-trifluoro-propyl)-piperidin-4-yl. In some embodiments, R 8 is 4-methoxy-pyridin-2-yl. In some embodiments, R 8 is 3-azepan-l-yl-2,2- dimethyl-propyl. In some embodiments, R 8 is l-(tert-butoxycarbonyl)azetidin-3-yl. In some embodiments, R 8 is 5-methyl-pyrazin-2 -ylmethyl. In some embodiments, R 8 is 1-oxo- hexahydro-l ⁇ 4 -thiopyran-4-yl.
  • R 8 is 2-(2-chloro-phenyl)-ethyl. In some embodiments, R 8 is 3-chloro-5-trifluoromethyl-pyridin-2 -ylmethyl. In some embodiments, R 8 is 2-hydroxy-l-hydroxymethyl-ethyl. In some embodiments, R 8 is (1 -methyl -pyrrolidin-2-yl)- pyridin-2-yl. In some embodiments, R 8 is 5-fluoro-2 -hydroxy-phenyl. In some embodiments, R 8 is methyl. In some embodiments, R 8 is 4-(methoxycarbonyl)-l-methylpiperidin-4-yl.
  • R 8 is 4-hydroxymethyl-l-methyl-piperidin-4-yl. In some embodiments, R 8 is 2- (2-hydroxymethyl-pyrrolidin-l-yl)-ethyl. In some embodiments, R 8 is 1-phenyl-cyclohexyl. In some embodiments, R 8 is 3 -methyl- l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 8 is 1-cyano-cyclohexyl. In some embodiments, R 8 is l-(5-methyl- [l,2,4]oxadiazol-3-yl)-cyclohexyl.
  • R 8 is 2-cyanopropan-2-yl. In some embodiments, R 8 is 3-methyl-l-phenylureido. In some embodiments, R 8 is l-carbamoyl-2,2- dimethyl-propyl. In some embodiments, R 8 is tert-butylamino. In some embodiments, R 8 is 2,2,2-trifluoro-l,l-dimethyl-ethyl. In some embodiments, R 8 is 2,2-dimethyl-l- methylcarbamoyl-propyl. In some embodiments, R 8 is 1-cyclopropyl-ethyl. In some embodiments,
  • R 8 is amino. In some embodiments, R 8 is N-/er/-butylmethylsulfonamido. In some embodiments, R 8 is l,l-dimethyl-prop-2-ynyl. In some embodiments, R 8 is 2-methyl-l- (phosphonooxy)propan-2-yl. In some embodiments, R 8 is l-tert-butyl-3-methylureido. In some embodiments, R 8 is 4-cyano-tetrahydro-pyran-4-yl. In some embodiments, R 8 is 1-methyl- cyclobutyl. In some embodiments, R 8 is l-hydroxymethyl-2-methyl-propyl. In some
  • R 8 is cyclobutylamino. In some embodiments, R 8 is 1-cyano-cyclopentyl. In some embodiments, R 8 is cyano-dimethyl-methyl. In some embodiments, R 8 is 2,2-dimethyl-l- (methylcarbamoyl)-propyl. In some embodiments, R 8 is phenylamino. In some embodiments, R 8 is 1-hydroxymethyl-propyl. In some embodiments, R 8 is l-methyl-l-(lH-tetrazol-5-yl)-ethyl. In some embodiments, R 8 is 3,3-dimethyl-l-(phosphonooxy)butan-2-yl).
  • R 8 is 2-hydroxy-l-tetrahydro-pyran-4-yl-ethyl. In some embodiments, R 8 is 1,2-dimethyl-propyl. In some embodiments, R 8 is l-pyridin-2-yl-cyclobutyl. In some embodiments, R 8 is 1- hydroxymethyl-2-phenyl-ethyl. In some embodiments, R 8 is 4-methylcarbamoyl-tetrahydro- pyran-4-yl. In some embodiments, R 8 is 1 -methyl- 1-methylcarbamoyl -ethyl. In some embodiments, R 8 is 2,2-dimethyl-l-morpholin-4-ylmethyl-propyl.
  • R 8 is l-methylcarbamoyl-cyclopent-S-enyl. In some embodiments, R 8 is 2-methoxy-2-oxo-l-(pyridin- 2-yl)ethyl. In some embodiments, R 8 is methylcarbamoyl-pyridin-2-yl-methyl. In some embodiments, R 8 is l-methylcarbamoyl-cyclopentyl. In some embodiments, R 8 is ⁇ - ⁇ tert- butylcarbamoyl)-2,2-dimethyl -propyl. In some embodiments, R 8 is 2,2-dimethyl-l-(pyridin-2- ylcarbamoyl)-propyl.
  • R 8 is l-(pyridin-2-ylcarbamoyl)-cyclobutyl. In some embodiments, R 8 is 1-methylcarbamoyl-cyclobutyl. In some embodiments, R 8 is 2- (methylamino)-2-oxo-l-phenylethyl. In some embodiments, R 8 is pyrrolidin-1-yl. In some embodiments, R 8 is piperidin-1-yl. In some embodiments, R 8 is 2,6-dimethyl-piperidin-l-yl. In some embodiments, R 8 is l-cyclopropylcarbamoyl-2,2-dimethyl -propyl.
  • R 8 is 2,2-dimethyl-l-(2,2,2-trifluoro-ethylcarbamoyl)-propyl. In some embodiments, R 8 is 1- ethylcarbamoyl-2,2-dimethyl-propyl. In some embodiments, R 8 is 2 -hydroxy- l-(tetrahydro- pyran-4-yl)-ethyl. In some embodiments, R 8 is N-cyclobutylmethylsulfonamido. In some embodiments, R 8 is N-phenylmethylsulfonamido. In some embodiments, R 8 is l-cyclopropyl-2- hydroxy-ethyl.
  • R 8 is 1,2,2-trimethyl-propyl. In some embodiments, R 8 is 2-oxo-l-(pyridin-2-yl)-2-(2,2,2-trifluoroethylamino)ethyl. In some embodiments, R 8 is 2,2- dimethyl-l-pyridin-2-yl-propyl. In some embodiments, R 8 is l-methoxy-3,3-dimethyl-l- oxobutan-2-yl. In some embodiments, R 8 is l-carboxy-2,2-dimethylpropyl. In some embodiments,
  • R 8 is l-(hydroxy-methyl-carbamoyl)-2,2-dimethyl-propyl. In some embodiments, R 8 is l-dimethylcarbamoyl-2,2-dimethyl-propyl. In some embodiments, R 8 is l-(azetidine-l- carbonyl)-2,2-dimethyl-propyl. In some embodiments, R 8 is l-methoxycarbamoyl-2,2-dimethyl- propyl. In some embodiments, R 8 is l-(methoxy-methyl-carbamoyl)-2,2-dimethyl-propyl.
  • R 8 is l-ter/-butoxycarbamoyl-2,2-dimethyl-propyl. In some embodiments, R 8 is 2,2-dimethyl-l-pyridin-2-yl-propyl. In some embodiments, R 8 is fluoromethyl. In some embodiments, R 8 is 2,2,2-trifluoroethylamino. In some embodiments, R 8 is (1,1-dioxo- tetrahydro-l ⁇ 6 -thiophen-3-yl)amino. In some embodiments, R 8 is l-hydroxycarbamoyl-2,2- dimethyl-propyl. In some embodiments, R 8 is l-hydroxymethyl-2 -methyl -butyl.
  • R 8 is l-(2-hydroxy-ethylcarbamoyl)-2,2-dimethyl -propyl. In some embodiments, R 8 is 1,1-t ⁇ -hydroxymethyl-propyl. In some embodiments, R 8 is l-(5-fluoro-pyridin-2-yl)-2,2- dimethyl-propyl. In some embodiments, R 8 is 4-hydroxymethyl-tetrahydro-2H-pyran-4-yl. In some embodiments, R 8 is l-(2-(te/ ⁇ butoxycarbonylarnino)-3-methylbutanoyloxy)-2- methylpropan-2-yl.
  • R 8 is l-(2-amino-3-methylbutanoyloxy)-3- methylbutan-2-yl. In some embodiments, R 8 is l-(2-amino-3-methylbutanoyloxy)-2- methylpropan-2-yl. In some embodiments, R 8 is 2-hydroxy-l-(tetrahydro-2H-pyran-4-yl)-ethyl. In some embodiments, R 8 is l-(4-carboxybutanoyloxy)-2 -methylpropan-2-yl. In some embodiments, R 8 is l-(4-carboxybutanoyloxy)-3-methylbutan-2-yl.
  • R 8 is l-(4-carboxybutanoyloxy)-3,3-dimethylbutan-2-yl. In some embodiments, R 8 is l-(2-amino-3- methylbutanoyloxy)-3,3-dimethylbutan-2-yl. In some embodiments, R 8 is 2-(2-amino-3- methylbutanoyloxy)-l-(tetrahydro-2H-pyran-4-yl)ethyl. In some embodiments, R 8 is 3,3,3- trifluoro-1-hydroxymethyl-propyl. In some embodiments, R 8 is 3 -fluoro-l-methoxy-3 -methyl- 1- oxobutan-2-yl.
  • R 8 is l-ethoxy-4,4,4-trifluoro-l-oxo-3- (trifluoromethyl)butan-2-yl. In some embodiments, R 8 is 2-fluoro-l-hydroxymethyl-2-methyl- propyl. In some embodiments, R 8 is l-(2-(tert-butoxycarbonylamino)-3-methylbutanoyloxy)- 3,3-dimethylbutan-2-yl. In some embodiments, R 8 is 4,4,4-trifluoro-l-methoxy-l-oxobutan-2-yl. In some embodiments, R 8 is 2-fluoro-l,l -dimethyl-ethyl.
  • R 8 is 3-fluoro- 2-(fluoromethyl)-l-methoxy-l-oxopropan-2-yl. In some embodiments, R 8 is 2-fluoro-l- fluoromethyl-1-hydroxymethyl-ethyl. In some embodiments, R 8 is 3-hydroxy-l-methoxy-2- methyl-l-oxopropan-2-yl. In some embodiments, R 8 is 2-carboxy-l-hydroxypropan-2-yl. In some embodiments, R 8 is 2,2,2-trifluoroethylamino. In some embodiments, R 8 is 1- fluoromethyl-2-methyl-propyl.
  • R 8 is l-fluoromethyl-2,2-dimethyl- propyl. In some embodiments, R 8 is 3-methyl-oxetan-3-yl. In some embodiments, R 8 is 1- fluoromethyl-cyclobutyl. In some embodiments, R 8 is l,l- ⁇ /s-hydroxymethyl-2-methyl-propyl. In some embodiments, R 8 is 1-trifluoromethyl-cyclopropyl. In some embodiments, R 8 is 1- methyl-cyclopropyl. In some embodiments, R 8 is 1-trifluoromethyl-cyclobutyl.
  • R 9 is selected from ⁇ , Ci-C 6 alkyl, and C 3 -C7 cycloalkyl.
  • R 9 is Ci-C 6 alkyl.
  • R 9 is C 3 -C 7 cycloalkyl.
  • R 9 is selected from ⁇ , methyl, tert-butyl, and cyclobutyl.
  • R 9 is ⁇ . In some embodiments, R 9 is methyl.
  • R 9 is tert-butyl
  • R 9 is cyclobutyl.
  • the Group R 10 is :
  • R 10 is selected from: C]-C 6 alkylene, heteroarylene, and heterocyclylene.
  • R 10 is selected from: 1,1-dimethylethylene, 1,1- dimethylmethylene, ethylene, methylene, 1 ,4-piperidinylene, 2,5-pyrazinylene, and 2,4- pyridinylene.
  • R 10 is C 1 -C 6 alkylene.
  • R 10 is selected from: 1,1-dimethylethylene, 1,1- dimethylmethylene, ethylene, and methylene.
  • R 10 is 1,1-dimethylethylene
  • R 10 is 1,1-dimethylmethylene.
  • R 10 is ethylene
  • R 10 is methylene
  • R 10 is heteroarylene
  • R 10 is selected from: 2,5-pyrazinylene, and 2,4-pyridinylene. In some embodiments, R 10 is heterocyclylene.
  • R 10 is 1 ,4-piperidinylene.
  • R 10 is absent.
  • R 11 is selected from: -C(O)NH- and C 1 -C 6 alkylene.
  • R 11 is selected from: -C(O)NH- and methylene.
  • R 1 ' is -C(O)NH-.
  • R 11 is C 1 -C 6 alkylene.
  • R 11 is methylene
  • R 11 is absent.
  • R 12 is C 1 -C 6 alkylene.
  • R 12 is methylene
  • R 12 is 1,1-dimethyl-methylene.
  • R 12 is absent.
  • the Group R 13 is the group R 12 :
  • R 13 is selected from: Ci-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkyl, Q- C 6 alkylamino, Ci-C 6 alkylsulfonyl, amino, C 3 -C 7 cycloalkyl, cyano, C 2 -C 8 dialkylamino, C r C 6 haloalkyl, halogen, and hydroxyl.
  • R 13 is selected from: Q-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, bromo, chloro, iodo, methoxy, cyano, methyl, tert-buty ⁇ , isopropyl, hydroxyl, ethyl, heptafluoropropyl, cyclobutyl, trifluoromethyl, cyclopropyl, dimethylamino, methoxy, ethoxy, methylamino, propyl, amino, and methanesulfonyl.
  • R 13 is selected from: C r C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, bromo, chloro, methoxy, cyano, methyl, tert-butyl, isopropyl, hydroxyl, ethyl, heptafluoropropyl, cyclobutyl, trifluoromethyl, cyclopropyl, dimethylamino, methoxy, ethoxy, methylamino, propyl, amino, and methanesulfonyl.
  • R 13 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 2- fluoro-4-methanesulfonyl -phenyl, 2,6-difluoro-phenyl, 2,5-difluoro-phenyl, 4-methoxy-phenyl, 4-cyano-phenyl, 4-fluoro-phenyl, phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, o-tolyl, tert-butyl, isopropyl, 2,2-dimethylpropyl, hydroxyl, 2-hydroxy-2-methylpropyl, 1-oxo-hexahydro-l ⁇ 4 - thiopyran-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydrothiopyran-4-yl, morpholin-4- yl
  • R 13 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 2- fluoro-4-methanesulfonyl-phenyl, 2,6-difluoro-phenyl, 2,5-difluoro-phenyl, 4-methoxy-phenyl, 4-cyano-phenyl, 4-fluoro-phenyl, phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, ⁇ -tolyl, tert-butyl, isopropyl, 2,2-dimethylpropyl, hydroxyl, 2-hydroxy-2-methylpropyl, 1-oxo-hexahydro-l ⁇ 4 - thiopyran-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydrothiopyran-4-yl, morpholin-4- yl,
  • R 13 is 2,4-difluoro-phenyl. In some embodiments, R 13 is 2,4- dichloro-phenyl. In some embodiments, R 13 is 2-fluoro-4-methanesulfonyl-phenyl. In some embodiments, R 13 is 2,6-difluoro-phenyl. In some embodiments, R 13 is 2,5-difluoro-phenyl. In some embodiments, R 13 is 4-methoxy-phenyl. In some embodiments, R 13 is 4-cyano-phenyl. In some embodiments, R 13 is 4-fluoro-phenyl. In some embodiments, R 13 is phenyl. In some embodiments, R 13 is 2-fluoro-phenyl.
  • R 13 is 3-fluoro-phenyl. In some embodiments, R 13 is ⁇ -tolyl. In some embodiments, R 13 is tert-buty ⁇ . In some embodiments, R 13 is isopropyl. In some embodiments, R 13 is 2,2-dimethylpropyl. In some embodiments, R 13 is hydroxyl. In some embodiments, R 13 is 2-hydroxy-2-methylpropyl. In some embodiments, R 13 is l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl. In some embodiments, R 13 is 1,1-dioxo-hexahydro-l ⁇ 6 - thiopyran-4-yl. In some embodiments, R 13 is tetrahydrothiopyran-4-yl. In some embodiments, R 13 is morpholin-4-yl. In some embodiments, R 13 is tetrahydro-pyran-4-yl. In some embodiments, R 13 is morpholin-4-yl. In
  • R 13 is l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 13 is pyrazin-2-yl. In some embodiments, R 13 is 5-ethyl-pyrazin-2-yl. In some embodiments, R 13 is 5- hydroxy-pyrazin-2-yl. In some embodiments, R 13 is 5-isopropyl-pyrazin-2-yl. In some embodiments, R 13 is 5-heptafluoropropyl-pyrazin-2-yl. In some embodiments, R 13 is 5- cyclobutyl-pyrazin-2-yl. In some embodiments, R 13 is 5-methyl-pyrazin-2-yl.
  • R 13 is 6-ethyl-pyrazin-2-yl. In some embodiments, R 13 is 5-trifluoromethyl- pyrazin-2-yl. In some embodiments, R 13 is cyclopropyl. In some embodiments, R 13 is 5- cyclopropyl-pyrazin-2-yl. In some embodiments, R 13 is 6-chloro-pyrazin-2-yl. In some embodiments, R 13 is 5-dimethylamino-pyrazin-2-yl. In some embodiments, R 13 is 4-cyano- phenyl. In some embodiments, R 13 is 6-methoxy-pyridazin-3-yl. In some embodiments, R 13 is 6- chloro-pyridazin-3-yl.
  • R 13 is pyrimidin-5-yl. In some embodiments, R 13 is 6-dimethylamino-pyrazin-2-yl. In some embodiments, R 13 is 6-methoxy-pyrazin-2-yl. In some embodiments, R 13 is 2-pyrimidin-4-yl. In some embodiments, R 13 is 5-bromo-pyrazin-2-yl. In some embodiments, R 13 is 5-hydroxy-pyrazin-2-yl. In some embodiments, R 13 is 5-methoxy- pyrazin-2-yl. In some embodiments, R 13 is 5-ethoxypyrazin-2-yl. In some embodiments, R 13 is 5-methylamino-pyrazin-2-yl.
  • R 13 is 5-bromo-pyridin-2-yl. In some embodiments, R 13 is pyridin-3-yl. In some embodiments, R 13 is 5-trifluoromethyl-pyridin-2-yl. In some embodiments, R 13 is 5-isopropyl-pyridin-2-yl. In some embodiments, R 13 is 5- isopropyl-pyridin-2-yl. In some embodiments, R 13 is 5-methyl-pyridin-2-yl. In some embodiments, R 13 is 5-ethyl-pyridin-2-yl. In some embodiments, R 13 is 5-methoxy-pyridin-2-yl. In some embodiments, R 13 is 4-trifluoromethyl-pyridin-2-yl.
  • R 13 is 5- cyano-pyridin-2-yl. In some embodiments, R 13 is 5-dimethylamino-pyridin-2-yl. In some embodiments, R 13 is 4-methyl-pyridin-2-yl. In some embodiments, R 13 is 5-chloro-4-methyl- pyridin-2-yl. In some embodiments, R 13 is 5-chloro-4-trifluoromethyl-pyridin-2-yl. In some embodiments, R 13 is 4-trifluoromethyl-pyridin-2-yl. In some embodiments, R 13 is 3-fluoro- pyridin-2-yl. In some embodiments, R 13 is 6-methyl-4-trifluoromethyl-pyridin-2-yl.
  • R 13 is 3-methyl-pyridin-2-yl. In some embodiments, R 13 is 5-propyl-pyridin-2-yl. In some embodiments, R 13 is 5-cyclopropyl-pyridin-2-yl. In some embodiments, R 13 is 5-fluoro- pyridin-2-yl. In some embodiments, R 13 is 3,5-difluoro-pyridin-2-yl. In some embodiments, R 13 is 6-bromo-pyridin-3-yl. In some embodiments, R 13 is 5-bromo-pyridin-3-yl. In some embodiments, R 13 is 5,6-difluoro-pyridin-3-yl.
  • R 13 is 6-chloro-pyridin-3- yl. In some embodiments, R 13 is 3-fluoro-pyridin-4-yl. In some embodiments, R 13 is 5-cyano- pyridin-3-yl. In some embodiments, R 13 is pyridin-4-yl. In some embodiments, R 13 is 2-chloro- pyridin-4-yl. In some embodiments, R 13 is 2-methoxy-pyridin-4-yl. In some embodiments, R 13 is 6-methyl-pyridin-3-yl. In some embodiments, R 13 is /w-tolyl. In some embodiments, R 13 is thiazol-2-yl. In some embodiments, R 13 is cyclopentyl.
  • R 13 is 4-amino- pyridin-2-yl. In some embodiments, R 13 is 4-methoxy-pyridin-2-yl. In some embodiments, R 13 is 4-choro-pyridin-2-yl. In some embodiments, R 13 is 4-fluoro-pyridin-2-yl. In some embodiments, R 13 is 4-cyclopropyl-pyridin-2-yl. In some embodiments, R 13 is 4-bromo-pyridin-2-yl. In some embodiments, R 13 is 4-methanesulfonyl-pyridin-2-yl. In some embodiments, R 13 is 4-cyano- pyridin-2-yl. In some embodiments, R 13 is hydroxymethyl.
  • R 13 is 4-oxy- pyrazin-2-yl. In some embodiments, R 13 is 3-methyl-l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 13 is 5-chloro-3-fluoro-pyridin-2-yl. In some embodiments, R 13 is 3- fluoro-5-methoxy-pyridin-2-yl. In some embodiments, R 13 is 2-chloro-4-fluoro-phenyl. In some embodiments, R 13 is 6-fluoro-pyridin-3-yl. In some embodiments, R 13 is 6-cyano-pyridin-3-yl.
  • R 13 is 4-iodo-pyridin-2-yl. In some embodiments, R 13 is l-oxy-pyridinr3- yl. In some embodiments, R 13 is 4-hydroxy-pyridin-2-yl.
  • R 14 is selected from: C 1 -C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -
  • Ci-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: Q- C 6 alkoxycarbonyl, Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl and aryl are optionally substituted with one substituent selected from: Ci-C 6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl.
  • R 14 is selected from: Ci-C 6 alkylene and C 3 -C 7 cycloalkylene; wherein said Ci-C 6 alkylene is optionally substituted with one or more substituents selected from: Ci-C 6 alkyl, aryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl is optionally substituted with one substituent selected from: halogen, and hydroxyl.
  • R 14 is selected from: Ci-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -
  • Ci-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: methyl, tert-butyl, ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4- fluoro-phenyl, tert-butoxycarbonyl, carboxy, methoxymethyl, hydroxyethyl, tetrahydro-furanyl, 3H-imidazolylmethyl, hydroxyl, pyrrolidinyl, cyclopropyl, sec-butyl, 2,2,2-trifluoroethyl, 2- fluoropropan-2-yl, l,l,l,3,3,3-hexafluoropropan-2-yl, and fluoromethyl.
  • substituents selected from: methyl, tert-butyl, ethyl, tetrahydro-2H-pyranyl, isoprop
  • R 14 is selected from: C 1 -C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 - C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Ci -C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: methyl, tert-buty ⁇ , ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4- fluoro-phenyl, tert-butoxycarbonyl, carboxy, methoxymethyl, hydroxyethyl, tetrahydro-furanyl, 3H-imidazolylmethyl, hydroxyl, pyrrolidinyl, and cyclopropyl.
  • R 14 is selected from: Ci-C 6 alkylene and C 3 -C 7 cycloalkylene; wherein said Ci -C 6 alkylene is optionally substituted with one or more substituents selected from: tetrahydro-2H-pyranyl, hydroxyl, 2,2,2-trifluoroethyl, and fluoromethyl.
  • R 14 is selected from: methylene, ethylene, cyclopropylene, cyclobutylene, piperidinylene, pyridinylene, tetrahydropyranylene, thiazolylene, cyclohexylene, cyclopentylene, cyclopentenylene, dioxohexahydrothiopyranylene, pyrrolidinylene,
  • ethylene, methylene, piperidinylene, propylene, and pyrrolidinylene are each optionally substituted with one or more substituents selected from: methyl, tert -butyl, ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4-fluoro-phenyl, terf-butoxycarbonyl, carboxy, ..
  • R 14 is selected from: methylene, ethylene, cyclopropylene, cyclobutylene, piperidinylene, pyridinylene, tetrahydropyranylene, thiazolylene, cyclohexylene, cyclopentylene, cyclopentenylene, dioxohexahydrothiopyranylene, pyrrolidinylene,
  • piperidinylene, propylene, and pyrrolidinylene are each optionally substituted with one or more substituents selected from: methyl, ferf-butyl, ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4-fluoro-phenyl, fert-butoxycarbonyl, carboxy, methoxymethyl, hydroxyethyl, tetrahydro-furanyl, 3H-imidazolylmethyl, hydroxyl, pyrrolidinyl, and
  • R 14 is selected from: methylene, ethylene, 1 , 1 -cyclopropylene, 1,1 -dimethyl -methylene, 1, 1 -cyclobutylene, tert-butyl-methylene, 1 -methyl-4,4-piperidinylene, 4,4-tetrahydro-2H-pyranylene, methyl -methylene, 1,1 -cyclohexylene, 1,2-cyclohexylene, 1,1- dimethyl-ethylene, 1-tert-butyl-ethylene, 1 -ethyl -ethylene, 1-methyl-ethylene, l-(tetrahydro-2H- pyran-4-yl)-ethylene, isopropyl-methylene, 1,1 -cyclopentylene, benzyl-methylene, 4,4- cyclopent- 1 -enylene, 1 , 1 -dioxo-hexahydro-1 ⁇ 6 -4,4-thiopyranylene, 1 -terf
  • R 14 is selected from: methylene, ethylene, 1,1-cyclopropylene, 1,1 -dimethyl -methylene, 1,1-cyclobutylene, tert-butyl-methylene, 1 -methyl -4,4-piperidinylene, 4,4-tetrahydro-2H-pyranylene, methyl -methylene, 1,1-cyclohexylene, 1 ,2-cyclohexylene, 1,1- dimethyl-ethylene, 1 -tert-butyl-ethylene, 1 -ethyl -ethylene, 1 -methyl -ethylene, l-(tetrahydro-2H- pyran-4-yl)-ethylene, isopropyl -methylene, 1,1-cyclopentylene, benzyl -methylene, 4,4- cyclopent-1 -enylene, 1 , 1 -dioxo-hexahydro- 1 ⁇ 6 -4,4-thiopyranylene, 1
  • R 14 is selected from: 1,1-cyclopropylene, 1,1 -dimethyl - methylene, 1,1-cyclobutylene, terZ-butyl-methylene, 1,1 -dimethyl-ethylene, 1-terf-butyl- ethylene, l-(tetrahydro-2H-pyran-4-yl)-ethylene, isopropyl -methylene, 1 -hydroxymethyl- 1- methyl-ethylene, phenyl-methylene, 1-isopropyl-ethylene, l-(2,2,2-trifluoroethyl)-ethylene, and 1 , 1 -di(fluoromethyl)-ethylene.
  • R 14 is methylene. In some embodiments, R 14 is ethylene. In some embodiments, R 14 is 1,1-cyclopropylene. In some embodiments, R 14 is 1,1-dimethyl-methylene. In some embodiments, R 14 is 1,1-cyclobutylene. In some embodiments, R 14 is tert-butyl- methylene. In some embodiments, R 14 is 1 -methyl -4,4-piperidinylene. In some embodiments, R 14 is 4,4-tetrahydro-2H-pyranylene. In some embodiments, R 14 is methyl-methylene. In some embodiments, R 14 is 1,1-cyclohexylene. In some embodiments, R 14 is 1 ,2-cyclohexylene.
  • R 14 is 1,1-dimethyl-ethylene. In some embodiments, R 14 is 1-tert-butyl- ethylene. In some embodiments, R 14 is 1-ethyl-ethylene. In some embodiments, R 14 is 1-methyl- ethylene. In some embodiments, R 14 is l-(tetrahydro-2H-pyran-4-yl)-ethylene. In some embodiments, R 14 is isopropyl-methylene. In some embodiments, R 14 is 1,1-cyclopentylene. In some embodiments, R 14 is benzyl-methylene. In some embodiments, R 14 is 4,4-cyclopent-l- enylene.
  • R 14 is l,l-dioxo-hexahydro-l ⁇ 6 -4,4-thiopyranylene. In some embodiments, R 14 is l-fer/-butoxycarbonyl-4,4-piperidinylene. In some embodiments, R 14 is 1- (pyridin-4-yl)-ethylene. In some embodiments, R 14 is l-(pyridin-3-yl)-ethylene. In some embodiments, R 14 is l-(pyridin-2-yl)-ethylene. In some embodiments, R 14 is l-(4-fluoro- phenyl)-ethylene. In some embodiments, R 14 is 1-hydroxymethyl-l-methyl-ethylene.
  • R 14 is 1-carboxy-l-methyl-ethylene. In some embodiments, R 14 is 1- methoxymethyl -ethylene. In some embodiments, R 14 is 1-hydroxymethyl-ethylene. In some embodiments, R 14 is l-(l-hydroxyethyl)-ethylene. In some embodiments, R 14 is 1,1-dimethyl- ethylene. In some embodiments, R 14 is l-(tetrahydro-furan-3-yl)-ethylene. In some
  • R 14 is phenyl-methylene. In some embodiments, R 14 is 1 -(3H-imidazol-4- ylmethyl)-ethylene. In some embodiments, R 14 is l-(4-hydroxy-phenyl)-ethylene. In some embodiments, R 14 is benzyl-ethylene. In some embodiments, R 14 is (l-hydroxymethyl-2- methyl)-ethylene. In some embodiments, R 14 is 1-isopropyl-ethylene. In some embodiments, R 14 is pyridin-2-yl-methylene. In some embodiments, R 14 is 1,1-dimethyl-propylene. In some embodiments, R 14 is 2-hydroxy-propylene.
  • R 14 is (1-isobutyl-pyrrolidin- 3-yl)-methylene. In some embodiments, R 14 is 1,3-azetidinylene. In some embodiments, R 14 is 1,3-pyrrolidinylene. In some embodiments, R 14 is 1,3-piperidinylene. In some embodiments, R 14 is 1,4-piperidinylene. In some embodiments, R 14 is 2,4-thiazolylene. In some embodiments, R 14 is 3,4-pyridinylene. In some embodiments, R 14 is 2,4-pyridinylene. In some embodiments, R 14 is 2,5-pyridinylene. In some embodiments, R 14 is -SO 2 -.
  • R 14 is 2,5- pyridinylene. In some embodiments, R 14 is 1-cyclopropyl-ethylene. In some embodiments, R 14 is l-(sec-butyl)-ethylene. In some embodiments, R 14 is 1 -hydroxymethyl- 1-ethyl-ethylene. In some embodiments, R 14 is 1-isopropyl-ethylene. In some embodiments, R 14 is 1 -(2,2,2-trifluoroethyl)- ethylene. In some embodiments, R 14 is (2-fluoropropan-2-yl)-methylene. In some embodiments, R 14 is (l,l,l,3,3,3-hexafluoropropan-2-yl)-methylene.
  • R 14 is l-(2- fluoropropan-2-yl)-ethylene. In some embodiments, R 14 is (2,2,2-trifluoroethyl)-methylene. In some embodiments, R 14 is l,l-di(fluoromethyl)-ethylene. In some embodiments, R 14 is
  • R 14 is
  • R 14 (hydroxymethyl)(methyl)methylene. In some embodiments, R 14 is 3,3-oxetanylene. In some embodiments, R 14 is 1-hydroxymethyl-l-isopropyl-ethylene.
  • R 14 is absent.
  • the Group R 15 is absent.
  • R 15 is selected from: -C(O)NH-, -C(O)-, -C(O)O-, C 1 -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with Ci-C 6 alkyl.
  • R 15 is selected from: -C(O)NH-, -C(O)-, C r C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with C r Q alkyl.
  • R 15 is selected from: -C(O)NH-, -C(O)-, -C(O)O-, C, -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with methyl.
  • R 15 is selected from: -C(O)NH-, -C(O)-, C 1 -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with methyl.
  • R 15 is selected from: pyrrolidinylene, piperidinylene,
  • pyridinylene azetidinylene, -C(O)NH-, -C(O)-, -C(O)O-, morpholinylene, methylene, ethylene, cyclopropylene, tetrahydropyranylene, cyclopentylene, tetrahydrothiophenylene,
  • R 15 is selected from: pyrrolidinylene, piperidinylene,
  • pyridinylene azetidinylene, -C(O)NH-, -C(O)-, morpholinylene, methylene, ethylene, cyclopropylene, tetrahydropyranylene, cyclopentylene, tetrahydrothiophenylene,
  • R 15 is selected from: 1,3-pyrrolidinylene, 1 ,4-piperidinylene, 2,6- pyridinylene, 1,3-azetidinylene, -C(O)NH-, -C(O)-, -C(O)O-, 1 ,2-pyrrolidinylene, 2,4- morpholinylene, ethylene, methylene, 1,1 -cyclopentylene, 4,4-tetrahydro-2H-pyranylene, 3,3- tetrahydro-thiophenylene, 1,1 -cyclopropylene, l-methyl-4,4-piperidinylene, and 1-oxo- tetrahydro- 1 ⁇ 4 -3 ,3 -thiophenylene.
  • R 15 is selected from: 1,3-pyrrolidinylene, 1 ,4-piperidinylene, 2,6- pyridinylene, 1,3-azetidinylene, -C(O)NH-, -C(O)-, 1 ,2-pyrrolidinylene, 2,4-morpholinylene, ethylene, methylene, 1,1 -cyclopentylene, 4,4-tetrahydro-2H-pyranylene, 3,3-tetrahydro- thiophenylene, 1,1 -cyclopropylene, l-methyl-4 ,4-piperidinylene, and l-oxo-tetrahydro-l ⁇ 4 -3,3- thiophenylene.
  • R 15 is selected from: -C(O)NH- and -C(O)O-.
  • R 15 is 1,3-pyrrolidinylene. In some embodiments, R 15 is 1,4- piperidinylene. In some embodiments, R 15 is 2,6-pyridinylene. In some embodiments, R 15 is 1,3- azetidinylene. In some embodiments, R 15 is -C(O)NH-. In some embodiments, R 15 is -C(O)-. hi some embodiments, R 15 is 1,2-pyrrolidinylene. In some embodiments, R 15 is 2,4- morpholinylene. In some embodiments, R 15 is ethylene. In some embodiments, R 15 is methylene. In some embodiments, R 15 is 1,1-cyclopentylene. In some embodiments, R 15 is 4,4-tetrahydro- 2H-pyranylene. In some embodiments, R 15 is 3,3-tetrahydro-thiophenylene. In some
  • R 15 is 1,1-cyclopropylene. In some embodiments, R 15 is 1 -methyl -4,4- piperidinylene. In some embodiments, R 15 is l-oxo-tetrahydro-l ⁇ 4 -3,3-thiophenylene.
  • R 15 is absent.
  • R 16 is Ci-C 6 alkylene.
  • R 16 is selected from: ethylene, methylene, isopropyl-methylene, and propylene.
  • R 16 is selected from: methylene, isopropyl-methylene, and propylene.
  • R 16 is selected from: ethylene, and methylene.
  • R 16 is ethylene
  • R 16 is methylene
  • R 16 is absent.
  • R 17 is selected from: ⁇ , C 1 -C 6 alkoxy, Ci-C 6 alkyl, Ci-C 6 alkylamino, Ci-C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo-C]-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, Q-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, aryl, arylamino, ary
  • R 17 is selected from: ⁇ , Q-C 6 alkyl, Q-C 6 alkylamino, amino, aryl, carboxy, cyano, Cj-C 6 haloalkyl, heteroaryl, hydroxyl, and phosphonooxy; wherein said aryl is optionally substituted with one hydroxyl group.
  • R 17 is selected from: ⁇ , Ci-C 6 alkoxy, Cj-C 6 alkyl, Q-C 6 alkylamino, C]-C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo-Q-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, Cj-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, amino, aryl, arylamino,
  • R 17 is selected from: H, Ci-C 6 alkoxy, Ci-C 6 alkyl, Ci-C 6 alkylamino, Ci-C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo-Ci-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -C n bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, C 1 -C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, aryl, arylamino, ary
  • R 17 is selected from: H, Ci-C 6 alkyl, C]-C 6 alkylamino, amino, aryl, carboxy, cyano, C 3 -C 7 cycloalkyl, C r C 6 haloalkyl, heteroaryl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said aryl and C 3 -C 7 cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxyl and trifluoromethyl.
  • R 17 is selected from: H, amino, 1 -tert-butoxycarbonylamino, morpholin-4-yl, 4-methyl-piperidin-l-yl, piperidin-4-yl, l-tert-butoxycarbonyl-piperidin-3-yl, tetrahydro-thiopyran-4-yl, 1 -oxo-hexahydro- 1 ⁇ 4 -thiopyran-4-yl, tetrahydro-pyran-4-yl, pyrrolidin-1-yl, l-tert-butoxycarbonyl-azetidin-3-yl, 2,6-dimethyl-morpholin-4-yl, piperidin-1- yl, l-tert-butoxycarbonyl-piperidin-4-yl, l,l-dioxo-hexahydro-l ⁇ ⁇ -thiopyran-4-yl, tetrahydro- furan-2-yl
  • R 17 is selected from: H, amino, 1-tert-butoxycarbonylamino, morpholin-4-yl, 4-methyl-piperidin-l-yl, piperidin-4-yl, l-terf-butoxycarbonyl-piperidin-3-yl, tetrahydro-thiopyran-4-yl, 1 -oxo-hexahydro- 1 ⁇ 4 -thiopyran-4-yl, tetrahydro-pyran-4-yl, pyrrolidin-1-yl, l-tert-butoxycarbonyl-azetidin-3-yl, 2,6-dimethyl-morpholin-4-yl, piperidin-1- yl, l-tert-butoxycarbonyl-piperidin-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydro- furan-2-yl, l
  • R 17 is selected from: is selected from: amino, 2-hydroxy-indan- 1-yl, hydroxyl, carboxy, trifluoromethyl, methyl, tert-butyl, cyano, tert-butylamino, phosphonooxy, pyridin-2-yl, and fluoromethyl.
  • R 17 is ⁇ . In some embodiments, R 17 is amino. In some embodiments, R 17 is 1-tert-butoxycarbonylamino. In some embodiments, R 17 is morpholin-4-yl. In some embodiments, R 17 is 4-methyl-piperidin-l-yl. In some embodiments, R 17 is piperidin-4- yl. In some embodiments, R 17 is l-tert-butoxycarbonyl-piperidin-3-yl. In some embodiments, R 17 is tetrahydro-thiopyran-4-yl. In some embodiments, R 17 is l-oxo-hexahydro-l ⁇ 4 -thiopyran- 4-yl.
  • R 17 is tetrahydro-pyran-4-yl. In some embodiments, R 17 is pyrrolidin-1-yl. In some embodiments, R 17 is l-te/Y-butoxycarbonyl-azetidin-3-yl. In some embodiments, R 17 is 2,6-dimethyl-morpholin-4-yl. In some embodiments, R 17 is piperidin-1-yl. In some embodiments, R 17 is l-tert-butoxycarbonyl-piperidin-4-yl. In some embodiments, R 17 is l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl.
  • R 17 is tetrahydro-furan-2-yl. In some embodiments, R 17 is l-ethyl-pyrrolidin-2-yl . In some embodiments, R 17 is 1 -methyl - pyrrolidin-2-yl. In some embodiments, R 17 is morpholin-2-yl. In some embodiments, R 17 is 1- methyl-piperidin-2-yl. In some embodiments, R 17 is l-methyl-piperidin-4-yl. In some embodiments, R 17 is 4-hydroxy-l-methyl-piperidin-4-yl. In some embodiments, R 17 is thiomorpholin-4-yl. In some embodiments, R 17 is tetrahydro-furan-3-yl.
  • R 17 is l-tert-butoxycarbonyl-pyrrolidin-4-yl. In some embodiments, R 17 is 1,2,2,6,6- pentamethyl-piperidin-4-yl. In some embodiments, R 17 is l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3- yl. In some embodiments, R 17 is 4-methyl-morpholin-2-yl. In some embodiments, R 17 is 4-tert- butoxycarbonyl -morpholin-2-yl. In some embodiments, R 17 is l-isopropyl-piperidin-4-yl.
  • R 17 is 4-hydroxy-l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 17 is 3-methyl-l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl. In some embodiments, R 17 is phenyl. In some embodiments, R 17 is 2-hydroxy-indan-l-yl. In some embodiments, R 17 is indan-1-yl. In some embodiments, R 17 is cyclopentyl. In some embodiments, R 17 is 2-hydroxy- cyclopentyl. In some embodiments, R 17 is cyclobutyl.
  • R 17 is 2-hydroxy- cyclohexyl. In some embodiments, R 17 is l,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl. In some embodiments, R 17 is 6,6-dimethyl-bicyclo[3.1.1]hept-2-yl. In some embodiments, R 17 is 1-aza- bicyclo[2.2.2]oct-3-yl. In some embodiments, R 17 is 9-methyl-9-aza-bicyclo[3.3.1]non-l-yl. In some embodiments, R 17 is 3-azepan-l-yl. In some embodiments, R 17 is 2-fluoro-phenyl. In some embodiments, R 17 is 2-chloro-phenyl.
  • R 17 is 4-fluoro-phenyl. In some embodiments, R 17 is 4-chloro-phenyl. In some embodiments, R 17 is 3-fluoro-phenyl. In some embodiments, R 17 is 5-fluoro-2-methoxy-phenyl. In some embodiments, R 17 is 2-fluoro-4- methanesulfonyl-phenyl. In some embodiments, R 17 is 4-carboxy-2-fluoro-phenyl. In some embodiments, R 17 is 2,5-difluoro-phenyl. In some embodiments, R 17 is /n-tolyl. In some embodiments, R 17 is o-tolyl.
  • R 17 is 2,5-dimethyl-phenyl. In some embodiments, R 17 is 2,3-dimethyl-phenyl. In some embodiments, R 17 is 4-hydroxy-3-methoxy- phenyl. In some embodiments, R 17 is 2,4-dimethoxy-phenyl. In some embodiments, R 17 is 2,3- dimethoxy-phenyl . In some embodiments, R 17 is 3,5-dimethoxy-phenyl. In some embodiments, R 17 is 4-methoxy-phenyl. In some embodiments, R 17 is 3-methoxy-phenyl. In some embodiments,
  • R 17 is 2-methoxy-phenyl. In some embodiments, R 17 is 3 -hydroxy-phenyl. In some embodiments, R 17 is 4-hydroxy-phenyl. In some embodiments, R 17 is 2-hydroxy-phenyl. In some embodiments, R 17 is 5-fluoro-2-hydroxy-phenyl. In some embodiments, R 17 is 3- trifluoromethoxy-phenyl. In some embodiments, R 17 is 4-difluoromethoxy-phenyl. In some embodiments, R 17 is 3-difluoromethoxy-phenyl. In some embodiments, R 17 is 4-fluoro-phenoxy. In some embodiments, R 17 is 2-dimethylamino-phenyl.
  • R 17 is 4- dimethylamino-phenyl. In some embodiments, R 17 is 6-fluoro-4H-benzo[l,3]dioxin-8-yl. In some embodiments, R 17 is benzo[l,3]dioxol-5-yl. In some embodiments, R 17 is pyrimidin-2-yl. In some embodiments, R 17 is pyrimidin-4-yl. In some embodiments, R 17 is 2,6-dimethyl- pyrimidin-4-yl. In some embodiments, R 17 is pyridazin-3-yl. In some embodiments, R 17 is 5- methyl-pyrazin-2-yl.
  • R 17 is 6-methoxy-pyrimidin-4-yl. In some embodiments, R 17 is pyrazin-2-yl. In some embodiments, R 17 is 3,5-dimethyl-pyrazin-2-yl. In some embodiments, R 17 is 5-fluoro-2-oxo-2,3-dihydro-pyrimidin-4-yl. In some embodiments, R 17 is hydroxyl. In some embodiments, R 17 is methoxycarbonyl. In some embodiments, R 17 is ethoxycarbonyl. In some embodiments, R 17 is carboxy. In some embodiments, R 17 is 1- piperidin-1-yl. In some embodiments, R 17 is carboxamide. In some embodiments, R 17 is methoxy.
  • R 17 is trifluoromethyl. In some embodiments, R 17 is methyl. In some embodiments, R 17 is tert-butyl. In some embodiments, R 17 is diethylamino. In some embodiments, R 17 is dimethylamino. In some embodiments, R 17 is cyano. In some embodiments, R 17 is tert-butylamino. In some embodiments, R 17 is cyclopropyl. In some embodiments, R 17 is pyridin-3-yloxy. In some embodiments, R 17 is lH-tetrazol-5-yl. In some embodiments, R 17 is 5- methyl-[l,2,4]oxadiazol-3-yl. In some embodiments, R 17 is phosphonooxy. In some embodiments, R 17 is methyl. In some embodiments, R 17 is tert-butyl. In some embodiments, R 17 is diethylamino. In some embodiments, R 17 is dimethylamino. In some embodiments, R 17 is
  • R 17 is cyclobutylamino. In some embodiments, R 17 is phenylamino. In some embodiments, R 17 is l-tert-butyl-3-methylureido. In some embodiments, R 17 is 3-methyl-l- phenylureido. In some embodiments, R 17 is N-tert-butylmethylsulfonamido. In some embodiments, R 17 is l-cyclobutyl-3-methylureido. In some embodiments, R 17 is
  • R 17 is 5-hydroxy-lH-indol-3-yl.
  • R 17 is lH-benzoimidazol-2-yl. In some embodiments, R 17 is 5,7-dimethyl- pyrazolo[l,5-a]pyrimidin-2-yl. In some embodiments, R 17 is lH-benzoimidazol-2-yl. In some embodiments, R 17 is 2-(tert-butoxycarbonyl)- 3,4-dihydro-lH-isoquinoline-2-yl. In some embodiments, R 17 is quinolin-3-yl. In some embodiments, R 17 is quinolin-4-yl. In some embodiments, R 17 is 2-methyl-quinolin-4-yl. In some embodiments, R 17 is benzooxazol-2-yl.
  • R 17 is l-methyl-l,2,3,4-tetrahydro-quinolin-7-yl. In some embodiments, R 17 is 2,3-dihydro-benzofuran-3-yl. In some embodiments, R 17 is benzothiazol-2-yl. In some embodiments, R 17 is l,4-dimethyl-lH-pyrrol-2-yl. In some embodiments, R 17 is 3-methyl-3H- imidazol-4-yl. In some embodiments, R 17 is lH-imidazol-4-yl. In some embodiments, R 17 is 5- hydroxy-lH-pyrazol-3-yl.
  • R 17 is l-methyl-lH-pyrazol-3-yl. In some embodiments, R 17 is 4-pyridin-2-yl-thiazol-2-yl. In some embodiments, R 17 is 5-methyl-thiazol- 2-yl. In some embodiments, R 17 is oxazol-4-yl. In some embodiments, R 17 is 4-phenyl-thiazol-2- yl. In some embodiments, R 17 is 5-tert-butyl-isoxazol-3-yl. In some embodiments, R 17 is pyridin-2-yl. In some embodiments, R 17 is pyridin-3-yl. In some embodiments, R 17 is pyridin-4- yl.
  • R 17 is 3-hydroxy-pyridin-2-yl . In some embodiments, R 17 is 6- hydroxy-pyridin-3-yl. In some embodiments, R 17 is 3-hydroxy-pyridin-4-yl. In some embodiments, R 17 is 4-hydroxy-pyridin-2-yl. In some embodiments, R 17 is 6-hydroxy-pyridin-2- yl. In some embodiments, R 17 is 2-hydroxy-pyridin-3-yl. In some embodiments, R 17 is 2- methoxy-pyridin-3-yl. In some embodiments, R 17 is 5-methoxy-pyridin-2-yl. In some embodiments, R 17 is 4-methoxy-pyridin-2-yl.
  • R 17 is 2-methoxy-pyridin- 4-yl. In some embodiments, R 17 is 6-methoxy-pyridin-2-yl. In some embodiments, R 17 is 6- methoxy-pyridin-3-yl. In some embodiments, R 17 is 3-fluoro-pyridin-2-yl. In some embodiments,
  • R 17 is 2-fluoro-pyridin-3-yl. In some embodiments, R 17 is 6-fluoro-pyridin-2-yl. In some embodiments, R 17 is 5-fluoro-pyridin-2-yl. In some embodiments, R 17 is 6-fluoro- pyridin-3-yl. In some embodiments, R 17 is 3-fluoro-pyridin-4-yl. In some embodiments, R 17 is 3- methyl -pyridin-2-yl. In some embodiments, R 17 is 3-methyl-pyridin-4-yl. In some embodiments, R 17 is 6-methyl-pyridin-2-yl. In some embodiments, R 17 is 4-methyl-pyridin-2-yl.
  • R 17 is 6-methyl-pyridin-3-yl. In some embodiments, R 17 is 2-methyl-pyridin-3-yl. In some embodiments, R 17 is 5-trifluoromethyl-pyridin-2-yl. In some embodiments, R 17 is 6- trifluoromethyl-pyridin-3-yl. In some embodiments, R 17 is 4-trifluoromethyl-pyridin-2-yl. In some embodiments, R 17 is 3-chloro-5-trifluoromethyl-pyridin-2-yl. In some embodiments, R 17 is 4,6-dimethyl-pyridin-2-yl. In some embodiments, R 17 is 4,6-dimethyl-pyridin-2-yl. In some embodiments, R 17 is 4,6-dimethyl-pyridin-2-yl.
  • R 17 is 3-chloro-5-methyl-pyridin-2-yl. In some embodiments, R 17 is 6-cyano- pyridin-3-yl. In some embodiments, R 17 is 3-cyano-5-methyl-pyridin-2-yl. In some embodiments,
  • R 17 is 3-cyano-5-methyl-pyridin-2-yl. In some embodiments, R 17 is 3-chloro-5- methyl-pyridin-2-yl. In some embodiments, R 17 is 2-chloro-pyridin-3-yl. In some embodiments, R 17 is 5-chloro-pyridin-2-yl. In some embodiments, R 17 is 6-chloro-2 -methyl -pyridin-3-yl. In. some embodiments, R 17 is 6-chloro-pyridin-3-yl. In some embodiments, R 17 is 3-chloro-pyridin- 4-yl. In some embodiments, R 17 is 6-bromo-2-methyl-pyridin-3-yl.
  • R 17 is 5-bromo-3-methyl-pyridin-2-yl. In some embodiments, R 17 is 6-carboxypyridin-2-yl. In some embodiments, R 17 is 6-methanesulfonyl-4-methyl-pyridin-3-yl. In some embodiments, R 17 is 6- methanesulfonyl-4-methyl -pyridin-3-yl. In some embodiments, R 17 is 6-methanesulfonyl-2- methyl-pyridin-3-yl. In some embodiments, R 17 is 6-methanesulfonyl-pyridin-3-yl. In some embodiments, R 17 is 2,6-dimethoxy-pyridin-3-yl.
  • R 17 is 5-fluoro-l-oxy- pyridin-2-yl. In some embodiments, R 17 is l-oxy-pyridin-2-yl. In some embodiments, R 17 is 6- pyrrolidin-l-yl-pyridin-2-ylmethyl. In some embodiments, R 17 is 5-(l-methyl-pyrrolidin-2-yl)- pyridin-2-yl. In some embodiments, R 17 is 6-morpholin-4-yl-pyridm-2-yl. In some
  • R 17 is 6-morpholin-4-yl-pyridin-3-yl. In some embodiments, R 17 is ethynyl. In some embodiments, R 17 is tert-butyl(methyl)amino. In some embodiments, R 17 is 2,2,2- trifluoroethyl. In some embodiments, R 17 is N-cyclobutylmethylsulfonamido. In some embodiments, R 17 is N-phenylmethylsulfonamido. In some embodiments, R 17 is
  • R 17 is methoxy(methyl)amino. In some embodiments, R 17 is azetidin-1-yl. In some embodiments, R 17 is tert-butoxy. In some embodiments, R 17 is fluoromethyl. In some embodiments, R 17 is 2,2,2-trifluoroethylamino. In some embodiments, R 17 is (l,l-dioxo-tetrahydro-l ⁇ 6 -thiophen-3-yl)amino.
  • R 15 is selected from: -C(O)NH-, -C(O)-, C r C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with Ci -C 6 alkyl; or R 15 is absent; and
  • R 17 is selected from: H, Ci-C 6 alkoxy, C r C 6 alkyl, C,-C 6 alkylamino, C r C 6
  • alkylcarboxamide C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- Ci-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, C r C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, aryl, arylamino, aryloxy, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkyl, C 3 -C 7
  • cycloalkylamino, heteroaryl, heterobicyclyl, heterocyclyl, and ureyl are each optionally substituted with one or more substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, Ci-C 6 alkyl, Cj-C 6 alkylsulfonyl, amino, aryl, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 8 dialkylamino, Ci-C 6 haloalkoxy, C t -C 6 haloalkyl, halogen, heteroaryl, heterocyclyl, and hydroxyl.
  • substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkoxycarbonyl, Ci-C 6 alkyl, Cj-C 6 alkylsulfonyl, amino, aryl, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 8 dialkyla
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from: H and Q-C 6 alkyl.
  • R 1 and R 6 are each independently selected from: H, and Ci-C 6 alkyl; and R 2 , R 3 , R 4 , and R 5 are each H.
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from: H, methyl, and isopropyl.
  • R 1 is selected from: H and methyl; R 2 , R 3 , R 4 , and R 5 are each H; and R 6 is selected from: H and is isopropyl.
  • R 1 is methyl
  • R 2 , R 3 , R 4 , and R 5 are each H
  • R 6 is isopropyl
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each H.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-C]-C 6 -alkoxy, C]-C 6 alkoxy, Ci-C 6 alkyl, aryl, carbo-C]-C 6 -alkoxy, Q-C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl; wherein said aryl, Q-C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, C]-C 6 alkoxy, halogen, and hydroxyl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-cyclohexylmethyl-piperazin-l-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 5,7- dihydro-pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l -yl, 2 -phenyl -pyrrolidin-1 -yl, 2-pyridin-2-yl-thiomorpholin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l -yl, 4-hydroxy- piperidin-1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH- isoquinolin-2-yl, 7-methoxy-3,4-dihydro-lH- iso
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-cyclohexylmethyl-piperazin-l-yl. In some embodiments, R 8 andR 9 together with the nitrogen atom to which they are both bonded form hexahydro-pyrrolo[l ,2-a]pyrazin-2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 5,7-dihydro-pyrrolo[3,4-b]pyridin-6-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-methoxy-2,3-dihydro-indol-l-yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 2- phenyl-pyrrolidin-1-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 2-pyridin-2-yl-thiomorpholin-4-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 2-hydroxymethyl- 2,3-dihydro-indol-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-hydroxy-piperidin-l-yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form hexahydro-pyrrolo[l,2- a]pyrazin-2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin-2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 7- methoxy-3,4-dihydro-lH-isoquinolin-2-yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5- yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 5-fluoro-l,3-dihydro-isoindol-2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3-hydroxy-7,8-dihydro-5H- [l,6]naphthyridin-6-yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-(terf-butoxycarbonyl)-2-(hydroxymethyl)piperazin-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form l,3-dihydro-isoindol-2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3-trifluoromethyl-5,6-dihydro-8H-[l,2,4]triazolo[4,3- a]pyrazin-7-yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-morpholin-4-yl-piperidin-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3,4-dihydro-lH- isoquinolin-2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-(3-methoxy-pyridin-2-yl)-piperazin-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3-hydroxy-piperidin-l- yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-(3-chloro-phenyl)-piperazin-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 6-methoxy-3,4-dihydro-lH-isoquinolin- 2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form morpholin-4-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 2-hydroxymethyl-pyrrolidin-l-yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 1,3-dihydro- pyrrolo[3,4-c]pyridin-2-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3-pyridin-4-yl-pyrrolidin-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-(pyridin-2-yloxy)- piperidin-1-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3-pyridin-2-yl-pyrrolidin-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 7-methyl-3,4-dihydro-2H-
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3-pyridin-3-yl-pyrrolidin-l-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 3-hydroxy-pyrrolidin-l- yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4-(4,6-dimethyl-pyrimidin-2-yl)-piperazin-l-yl.
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 2-methyl-3,4-dihydro-2H- quinolin-1-yl. In some embodiments, R 8 and R 9 together with the nitrogen atom to which they are both bonded form 2-phenyl-morpholin-4-yl or pyrazin-2-yl.
  • Some embodiments of the present invention pertain to compounds of Formula Ic and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 1 and R 6 are each independently selected from: H, and Ci-C 6 alkyl; X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R"-R 12 -R 13 ; wherein:
  • R 10 is selected from: C 1 -C 6 alkylene, heteroarylene, and heterocyclylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and Ci -C 6 alkylene; or R 11 is absent;
  • R 12 is C]-C 6 alkylene; or R 12 is absent;
  • R 13 is selected from: Ci-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci -C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkyl, Ci-C 6 alkylamino, Ci-C 6 alkylsulfonyl, amino, C 3 -C 7 cycloalkyl, cyano, C 2 -C 8 dialkylamino, Ci-C 6 haloalkyl, halogen, and hydroxyl;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: Q-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Q-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: Ci-C 6 alkoxycarbonyl, Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said Q- C 6 alkyl and aryl are optionally substituted with one substituent selected from: Ci-C 6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH-, -C(O)-, -C(O)O-, Q-C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with Ci-C 6 alkyl; or R 15 is absent;
  • R 16 is Ci-C 6 alkylene; or R 16 is absent;
  • R 17 is selected from: H, Q-C 6 alkoxy, Q-C 6 alkyl, Q-C 6 alkylamino, Q-C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- Q-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -Cs dialkylamino, C 2 -Cg dialkylsulfonamide, Ci-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, amino, aryl, arylamino, aryloxy, C 5
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkyl, aryl, carbo-Ci-C 6 -alkoxy, Ci-C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl; wherein said aryl, Q-C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, C]-C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ic and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 1 and R 6 are each independently selected from: H, and Ci-C 6 alkyl
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R ⁇ -R 12 -R 13 ; wherein:
  • R 10 is selected from: Q-C 6 alkylene, heteroarylene, and heterocyclylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and Q-C 6 alkylene; or R 11 is absent;
  • R 12 is C]-C 6 alkylene; or R 12 is absent;
  • R 13 is selected from: C]-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkyl, Ci-C 6 alkylamino, C]-C 6 alkylsulfonyl, amino, C 3 -C 7 cycloalkyl, cyano, C 2 -C 8 dialkylamino, Q-C 6 haloalkyl, halogen, and hydroxyl; R 8 is -R 14 -R I5 -R 16 -R 17 ; wherein:
  • R 14 is selected from: Ci-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Q-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: Ci-C 6 alkoxycarbonyl, C]-C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said C r C 6 alkyl and aryl are optionally substituted with one substituent selected from: C]-C 6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH-, -C(O)-, C,-C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with Ci-C 6 alkyl; or R 15 is absent;
  • R 16 is C]-C 6 alkylene; or R 16 is absent;
  • R 17 is selected from: H, Q-C 6 alkoxy, C]-C 6 alkyl, Ci-C 6 alkylamino, C]-C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- Ci-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cu bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, C]-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, aryl, arylamino, aryloxy, C 5
  • cycloalkylamino, heteroaryl, heterobicyclyl, heterocyclyl, and ureyl are each optionally substituted with one or more substituents selected from: Cj-C 6 alkoxy, Cj-C 6 alkoxycarbonyl, C]-C 6 alkyl, C 1 -C 6 alkylsulfonyl, amino, aryl, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 8 dialkylamino, Cj-C 6 haloalkoxy, Ci-C 6 haloalkyl, halogen, heteroaryl, heterocyclyl, and hydroxyl; and R 9 is selected from H, Cj-C 6 alkyl, and C 3 -C 7 cycloalkyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-Ci-C 6 -alkoxy, Ci-C 6 alkoxy, Ci-C 6 alkyl, aryl, carbo-Cj-C 6 - alkoxy, Cj-C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl;
  • aryl, C r C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ic and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 1 and R 6 are each independently selected from: H, and Ci-C 6 alkyl
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R u -R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1 , 1 -dimethylmethylene, ethylene, methylene, 1 ,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is methylene; or R 12 is absent;
  • R 13 is selected from: Ci-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Q-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, bromo, chloro, iodo, methoxy, cyano, methyl, tert- butyl, isopropyl, hydroxyl, ethyl, heptafluoropropyl, cyclobutyl, trifluoromethyl, cyclopropyl, dimethylamino, methoxy, ethoxy, methylamino, propyl, amino, and methanesulfonyl; R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: Ci-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Cj-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: methyl, tert-butyl, ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4-fluoro-phenyl, tert- butoxycarbonyl, carboxy, methoxymethyl, hydroxyethyl, tetrahydro-furanyl, 3H- imidazolylmethyl, hydroxyl, pyrrolidinyl, cyclopropyl, sec-butyl, 2,2,2-trifluoroethyl, 2- fluoropropan-2-yl, l,l,l,3,3,3-hexafluor
  • R 15 is selected from: -C(O)NH-, -C(O)-, -C(O)O-, Q-C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with methyl; or R 15 is absent;
  • R 16 is selected from: ethylene, methylene, isopropyl-methylene, and propylene; or R 16 is absent; and R 17 is selected from: H, Ci-C 6 alkoxy, C 1 -C 6 alkyl, Ci-C 6 alkylamino, C 1 -C 6
  • alkylcarboxamide C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- C ! -C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, Ci-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said C r C 6 alkylamino, amino, aryl, arylamino, aryloxy, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyla
  • R 9 is selected from H, C]-C 6 alkyl, and C 3 -C 7 cycloalkyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-Ci-C 6 -alkoxy, Ci-C 6 alkoxy, C r C 6 alkyl, aryl, carbo-Ci-C 6 - alkoxy, Ci-C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl;
  • aryl, Ci-C 6 alkyl, and heteroaryl are optionally substituted with one substiruent selected from: C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ic and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 1 and R 6 are each independently selected from: H, and Ci-C 6 alkyl
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R"-R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1,1-dimethylmethylene, ethylene, methylene, 1 ,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is methylene; or R 12 is absent;
  • R 13 is selected from: C]-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, bromo, chloro, methoxy, cyano, methyl, tert-butyl, isopropyl, hydroxyl, ethyl, heptafluoropropyl, cyclobutyl, trifluoromethyl, cyclopropyl, dimethylamino, methoxy, ethoxy, methylamino, propyl, amino, and methanesulfonyl;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: Ci-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Ci-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: methyl, tert-butyl, ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4-fluoro-phenyl, tert- butoxycarbonyl, carboxy, methoxymethyl, hydroxyethyl, tetrahydro-furanyl, 3H- imidazolylmethyl, hydroxyl, pyrrolidinyl, and cyclopropyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH-, -C(O)-, C 1 -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with methyl; or R 15 is absent;
  • R 16 is selected from: ethylene and methylene; or R 16 is absent;
  • R 17 is selected from: H, C r C 6 alkoxy, C r C 6 alkyl, C 1 -C 6 alkylamino, Ci-C 6
  • alkylcarboxamide C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- Ci-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cu bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, Ci-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, aryl, arylamino, aryloxy, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkyl, C 3 -C 7
  • cycloalkylamino, heteroaryl, heterobicyclyl, heterocyclyl, and ureyl are each optionally substituted with one or more substituents selected from: amino, 1-tert-butoxycarbonylamino, methyl, 1 -/er/-butoxycarbonyl, ethyl, hydroxyl, isopropyl, tert-butyl, fluoro, chloro, methoxy, methanesulfonyl, carboxy, trifluoromethoxy, difluoromethoxy, dimethylamino,
  • R 9 is selected from H, Ci-C 6 alkyl, and C 3 -C 7 cycloalkyl; or R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-Ci-C 6 -alkoxy, Ci-C 6 alkoxy, C 1 -C 6 alkyl, aryl, carbo-Ci-C 6 - alkoxy, Ci-C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl;
  • aryl, Ci-C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ic and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 1 is selected from: H and methyl
  • R 6 is selected from: H and isopropyl
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R u -R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1,1-dimethylmethylene, ethylene, methylene, 1,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is 1,1 -dimethyl -methylene; or R 12 is absent;
  • R 13 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 2-fluoro-4- methanesulfonyl-phenyl, 2,6-difluoro-phenyl, 2,5-difluoro-phenyl, 4-methoxy-phenyl, 4-cyano- phenyl, 4-fluoro-phenyl, phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, o-tolyl, tert-butyl, isopropyl, 2,2-dimethylpropyl, hydroxyl, 2-hydroxy-2-methylpropyl, l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydrothiopyran-4-yl, morpholin-4-yl, te
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: methylene, ethylene, 1,1-cyclopropylene, 1,1 -dimethyl -methylene,
  • R 15 is selected from: 1,3-pyrrolidinylene, 1 ,4-piperidinylene, 2,6-pyridinylene, 1,3- azetidinylene, -C(O)NH-, -C(O)-, -C(O)O-, 1,2-pyrrolidinylene, 2,4-morpholinylene, ethylene, methylene, 1,1-cyclopentylene, 4,4-tetrahydro-2H-pyranylene, 3,3-tetrahydro-thiophenylene, 1,1-cyclopropylene, l-methyl-4,4-piperidinylene, and l-oxo-tetrahydro-l ⁇ 4 -3,3-thiophenylene; or R 15 is absent;
  • R 16 is selected from: ethylene and methylene; or R 16 is absent;
  • R 17 is selected from: is selected from: ⁇ , amino, 1 -terf-butoxycarbonylamino, morpholin-4-yl, 4-methyl-piperidin-l-yl, piperidin-4-yl, l-tert-butoxycarbonyl-piperidin-3-yl, tetrahydro-thiopyran-4-yl, 1 -oxo-hexahydro-1 ⁇ 4 -thiopyran-4-yl, tetrahydro-pyran-4-yl, pyrrolidin-1-yl, l-terf-butoxycarbonyl-azetidin-3-yl, 2,6-dimethyl-morpholin-4-yl, piperidin-1- yl, l-tert-butoxycarbonyl-piperidin-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydro- furan-2-yl,
  • R 9 is selected from ⁇ , methyl, tert-buty ⁇ , and cyclobutyl; or R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-1 -yl, hexahydro-pyrrolo[l ,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomo ⁇ holin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l -yl, 4-hydroxy-piperidin- 1 -yl, hexahydro-pyrrolo[ 1 ,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-di
  • R 1 is selected from: ⁇ and methyl
  • R 6 is selected from: ⁇ and isopropyl
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is -R 10 -R u -R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1,1-dimethylmethylene, ethylene, methylene, 1 ,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is 1,1-dimethyl-methylene; or R 12 is absent;
  • R 13 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 2-fluoro-4- methanesulfonyl-phenyl, 2,6-difluoro-phenyl, 2,5-difluoro-phenyl, 4-methoxy-phenyl, 4-cyano- phenyl, 4-fluoro-phenyl, phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, o-tolyl, tert-butyl, isopropyl, 2,2-dimethylpropyl, hydroxyl, 2-hydroxy-2-methylpropyl, l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydrothiopyran-4-yl, mo ⁇ holin-4-yl, t
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: methylene, ethylene, 1,1-cyclopropylene, 1,1 -dimethyl -methylene, 1,1-cyclobutylene, tert-buty ⁇ -methylene, 1 -methyl -4,4-piperidinylene, 4,4-tetrahydro-2H- pyranylene, methyl-methylene, 1,1-cyclohexylene, 1 ,2-cyclohexylene, 1,1-dimethyl-ethylene, 1- ter/-butyl -ethylene, 1-ethyl-ethylene, 1 -methyl -ethylene, l-(tetrahydro-2H-pyran-4-yl)-ethylene, isopropyl-methylene, 1,1-cyclopentylene, benzyl -methylene, 4,4-cyclopent-l-enylene, 1,1- dioxo-hexahydro- 1 ⁇ 6 -4,4-thiopyranylene, 1 -fer?-butoxycarbonyl-4,
  • R 15 is selected from: 1,3-pyrrolidinylene, 1 ,4-piperidinylene, 2,6-pyridinylene, 1,3- azetidinylene, -C(O)NH-, -C(O)-, 1,2-pyrrolidinylene, 2,4-morpholinylene, ethylene, methylene, 1,1-cyclopentylene, 4,4-tetrahydro-2H-pyranylene, 3,3-tetrahydro-thiophenylene, 1,1- cyclopropylene, l-methyl-4,4-piperidinylene, and l-oxo-tetrahydro-l ⁇ 4 -3,3-thiophenylene; or R 15 is absent;
  • R 16 is selected from: ethylene and methylene; or R 16 is absent;
  • R 17 is selected from: H, amino, 1-tert-butoxycarbonylamino, morpholin-4-yl, 4-methyl- piperidin-1-yl, piperidin-4-yl, l-/ert-butoxycarbonyl-piperidin-3-yl, tetrahydro-thiopyran-4-yl, l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl, tetrahydro-pyran-4-yl, pyrrolidin-1-yl, ⁇ -tert- butoxycarbonyl-azetidin-3-yl, 2,6-dimethyl-mo ⁇ holin-4-yl, piperidin-1-yl, ⁇ -tert- butoxycarbonyl-piperidin-4-yl, 1 , 1 -dioxo-hexahydro- 1 ⁇ 6 -thiopyran-4-yl, tetrahydro-furan-2-yl, 1 -
  • R 9 is selected from H, methyl, tert-buty ⁇ , and cyclobutyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-l-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomorpholin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l -yl, 4-hydroxy-piperidin- 1 -yl, hexahydro-pyrrolo[ 1 ,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3 ,4-dihydro- lH-isoquinolin- 2-yl, 7-methoxy-3 ,4-dihydro
  • Some embodiments of the present invention pertain to compounds of Formula Ic and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 1 is selected from: ⁇ and methyl
  • R 6 is selected from: ⁇ and isopropyl
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is selected from: 2,4-difluoro-phenyl, 5-bromo-pyridin-2-yl, 4-cyano-phenyl, pyridin-3-yl, pyridin-2-yl, 5-thiazol-2-yl-pyridin-2-yl, 5-trifluoromethyl-pyridin-2-yl, 5- ⁇ -tolyl- pyridin-2-yl, 5-dimethylamino-pyrazin-2-yl, 2,4-dichloro-phenyl, 5-isopropyl-pyridin-2-yl, 5- methyl-pyridin-2-yl, 5-(4-methoxy-phenyl)-pyridin-2-yl, 2-fluoro-4-methanesulfonyl-phenyl, 2- fluoro-phenyl, 5-chloro-pyridin-2-yl, 5-brom
  • R 9 is selected from H, methyl, tert-butyl, and cyclobutyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin- 1 -yl, hexahydro-pyrrolo[ 1 ,2-a]pyrazin-2-yl, 5 ,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomo ⁇ holin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l -yl, 4-hydroxy-piperidin- 1 -yl, hexahydro-pyrrolo[ 1 ,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3 ,4-dihydro- lH-isoquinolin- 2-yl, 7-methoxy-3
  • R 1 is selected from: H and methyl
  • R 6 is selected from: H and isopropyl; X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is selected from: 2,4-difluoro-phenyl,5-bromo-pyridin-2-yl, 4-cyano-phenyl, pyridin- 3-yl, pyridin-2-yl, 5-thiazol-2-yl-pyridin-2-yl, 5-trifluoromethyl-pyridin-2-yl, 5- ⁇ -tolyl-pyridin- 2-yl, 5-dimethylamino-pyrazin-2-yl, 2,4-dichloro-phenyl, 5 -isopropyl -pyridin-2-yl, 5 -methyl - pyridin-2-yl, 5-(4-methoxy-phenyl)-pyridin-2-yl, 2-fluoro-4-methanesulfonyl-phenyl, 2-fluoro- phenyl, 5-chloro-pyridin-2-yl, 5-bromo-pyridin-3-yl, tert-butyl, 2-me
  • R 9 is selected from H, methyl, tert-butyl, and cyclobutyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin- 1 -yl, hexahydro-pyrrolo[ 1 ,2-a]pyrazin-2-yl, 5 ,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomorpholin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l-yl, 4-hydroxy-piperidin- 1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin- 2-yl, 7-methoxy-3,4-dihydro-lH
  • R 1 is H
  • R 6 is H
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or
  • X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is selected from: 2,4-difluoro-phenyl, 5-bromo-pyridin-2-yl, 4-cyano-phenyl, pyridin-3-yl, pyridin-2-yl, 5-thiazol-2-yl-pyridin-2-yl, 5-trifluoromethyl-pyridin-2-yl, 5-o-tolyl- pyridin-2-yl, 5-dimethylamino-pyrazin-2-yl, 2,4-dichloro-phenyl, 5 -isopropyl -pyridin-2-yl, 5- methyl-pyridin-2-yl, 5-(4-methoxy-phenyl)-pyridin-2-yl, 2-fluoro-4-methanesulfonyl-phenyl, 2- fluoro-phenyl, 5-chloro-pyridin-2-yl,
  • R 9 is selected from H, methyl, tert-butyl, and cyclobutyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-1 -yl, hexahydro-pyrrolo[l ,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomorpholin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l -yl, 4-hydroxy-piperidin- 1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin- 2-yl, 7-methoxy-3,4-dihydro-lH-is
  • R 1 is ⁇
  • R 6 is ⁇
  • X is NR 7 and Y is CC(O)N(R 8 )R 9 ; or X is CC(O)N(R 8 )R 9 and Y is NR 7 ;
  • R 7 is selected from: 2,4-difluoro-phenyl,5-bromo-pyridin-2-yl, 4-cyano-phenyl, pyridin- 3-yl, pyridin-2-yl, 5-thiazol-2-yl-pyridin-2-yl, 5-trifluoromethyl-pyridin-2-yl, 5-o-tolyl-pyridin- 2-yl, 5-dimethylamino-pyrazin-2-yl, 2,4-dichloro-phenyl, 5-isopropyl-pyridin-2-yl, 5-methyl- pyridin-2-yl, 5-(4-methoxy-phenyl)-pyridin-2-yl, 2-fluoro-4-methanesulfonyl-phenyl, 2-fluoro- phenyl, 5-chloro-pyridin-2-yl, 5-bromo-pyridin-3-yl, tert-buty ⁇ , 2-methoxy-pyridin
  • R 8 is selected from: H, 2-methyl-2-morpholin-4-yl-propyl, 1 -hydroxymethyl-2,2- dimethyl-propyl, 2-(fer/-butoxycarbonylamino)cyclohexyl, 1-phenyl-cyclopropyl, 5- trifluoromethyl -pyridin-2-yl, 1 -methyl- 1 -phenyl-ethyl, 1 -(2-methoxy-ethyl)-pyrrolidin-3 - ylmethyl, l-(methoxycarbonyl)cyclopropyl, tetrahydro-pyran-4-ylmethyl,
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-1 -yl, hexahydro-pyrrolo[l ,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridm-2-yl-thiomorpholin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l-yl, 4-hydroxy-piperidin- 1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin- 2-yl, 7-methoxy-3,4-dihydro-lH-is
  • Some embodiments of the present invention pertain to compounds of Formula Id and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof: wherein:
  • X is NR 7 and Y is CC(O)NHR 8 ;
  • X is CC(O)NHR 8 and Y is NR 7 ;
  • R 7 is selected from: aryl and heteroaryl; wherein said aryl and heteroaryl are each optionally substituted with one or two substituents selected from: cyano and halogen;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: C 1 -C 6 alkylene and C 3 -C 7 cycloalkylene; wherein said Cj-C 6 alkylene is optionally substituted with one or more substituents selected from: Ci-C 6 alkyl, aryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl is optionally substituted with one substituent selected from: halogen, and hydroxyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH- and -C(O)O-; or R 15 is absent;
  • R 16 is Ci-C 6 alkylene; or R 16 is absent;
  • R 17 is selected from: H, Ci-C 6 alkyl, Ci-C 6 alkylamino, amino, aryl, carboxy, cyano, C 1 -
  • Some embodiments of the present invention pertain to compounds of Formula Id and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • X is NR 7 and Y is CC(O)NHR 8 ;
  • X is CC(O)NHR 8 and Y is NR 7 ;
  • R 7 is selected from: aryl and heteroaryl; wherein said aryl and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, chloro, and cyano;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: C 1 -C 6 alkylene and C 3 -C 7 cycloalkylene; wherein said Ci-C 6 alkylene is optionally substituted with one or more substituents selected from: tetrahydro-2H- pyranyl, hydroxyl, 2,2,2-trifluoroethyl, and fluoromethyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH- and -C(O)O-; or R 15 is absent;
  • R 16 is selected from: methylene, isopropyl-methylene, and propylene; or R 16 is absent; and
  • R 17 is selected from: H, Q-C 6 alkyl, Q-C 6 alkylamino, amino, aryl, carboxy, cyano, C 3 - C 7 cycloalkyl, Ci-C 6 haloalkyl, heteroaryl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said aryl and C 3 -C 7 cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxyl and trifluoromethyl.
  • Some embodiments of the present invention pertain to compounds of Formula Id and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • X is NR 7 and Y is CC(O)NHR 8 ;
  • X is CC(O)NHR 8 and Y is NR 7 ;
  • R 7 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 5-chloro-pyridin-2-yl, 5- cyano-pyrazin-2-yl, pyrazin-2-yl, 5-fluoro-pyridin-2-yl, 4-chloro-pyridin-2-yl, 4-fluoro-pyridin- 2-yl, 4-cyano-pyridin-2-yl, and 4-oxy-pyrazin-2-yl;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: 1,1-cyclopropylene, 1,1-dimethyl-methylene, 1,1-cyclobutylene, tert-butyl -methylene, 1,1-dimethyl-ethylene, 1-tert-butyl-ethylene, l-(tetrahydro-2H-pyran-4- yl)-ethylene, isopropyl-methylene, 1-hydroxymethyl-l -methyl -ethylene, phenyl-methylene, 1- isopropyl-ethylene, l-(2,2,2-trifluoroethyl)-ethylene, and l,l-di(fluoromethyl)-ethylene; or R 14 is absent;
  • R 15 is selected from: -C(O)NH- and -C(O)O-; or R 15 is absent;
  • R 16 is selected from: methylene, isopropyl-methylene, and propylene; or R 16 is absent; and
  • R 17 is selected from: is selected from: amino, 2-hydroxy-indan-l-yl, hydroxyl, carboxy, trifluoromethyl, methyl, tert-butyl, cyano, tert-butylamino, phosphonooxy, pyridin-2-yl, and fluoromethyl.
  • Some embodiments of the present invention pertain to compounds of Formula Id and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • X is NR 7 and Y is CC(O)NHR 8 ;
  • X is CC(O)NHR 8 and Y is NR 7 ;
  • R 7 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 5-chloro-pyridin-2-yl, 5- cyano-pyrazin-2-yl, pyrazin-2-yl, 5-fluoro-pyridin-2-yl, 4-chloro-pyridin-2-yl, 4-fluoro-pyridin- 2-yl, 4-cyano-pyridin-2-yl, and 4-oxy-pyrazin-2-yl; and
  • R 8 is selected from: l-hydroxyrnethyl-2,2-dimethyl-propyl, 2-hydroxy- 1,1 -dimethyl- ethyl, 1-hydroxymethyl-cyclopropyl, 2-hydroxy-indan-l-yl, 1-hydroxymethyl-cyclobutyl, tert- butyl, 2-hydroxy- 1-phenyl-ethyl, 2-hydroxy- 1-hydroxymethyl-l -methyl -ethyl, tert-butylamino, 2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl, 2-methyl-l -(phosphonooxy)propan-2-yl, 1 -methyl - cyclobutyl, 1-hydroxymethyl -2 -methyl -propyl, cyano-dimethyl-methyl, 2,2-dimethyl-l- (methylcarbamoyl)-propyl, 3,3-dimethyl-l-(phosphonooxy)butan-2-yl, 2-hydroxy-l-tetra
  • Some embodiments of the present invention pertain to compounds of Formula Ie and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 7 is -R 10 -R ⁇ -R 12 -R 13 ; wherein:
  • R 10 is selected from: C 1 -C 6 alkylene, heteroarylene, and heterocyclylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and Cj-C 6 alkylene; or R 11 is absent;
  • R 12 is Ci-C 6 alkylene; or R 12 is absent;
  • R 13 is selected from: C 1 -C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said C 1 -C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: C 1 -C 6 alkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, Ci-C 6 alkylsulfonyl, amino, C 3 -C 7 cycloalkyl, cyano, C 2 -C 8 dialkylamino, C 1 -C 6 haloalkyl, halogen, and hydroxyl;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: C]-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Ci-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: Ci-C 6 alkoxycarbonyl, C r C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said Q- C 6 alkyl and aryl are optionally substituted with one substituent selected from: Ci-C 6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl; or R is absent; R 15 is selected from: -C(O)NH-, -C(O)-, -C(O)O-, C r C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocycl
  • R 16 is Ci-C 6 alkylene; or R 16 is absent;
  • R 17 is selected from: H, Q-C 6 alkoxy, C 1 -C 6 alkyl, C,-C 6 alkylamino, C 1 -C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- C]-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -C n bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, C 1 -C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Cj-C 6 alkylamino, aryl, arylamino,
  • R 9 is selected from H, C 1 -C 6 alkyl, and C 3 -C 7 cycloalkyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-C r C 6 -alkoxy, C r C 6 alkoxy, C 1 -C 6 alkyl, aryl, carbo-Ci-C 6 - alkoxy, C 1 -C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl;
  • aryl, C 1 -C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ie and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 7 is -R 10 -R ⁇ -R 12 -R 13 ; wherein:
  • R 10 is selected from: C 1 -C 6 alkylene, heteroarylene, and heterocyclylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and C 1 -C 6 alkylene; or R 11 is absent;
  • R 12 is Ci-C 6 alkylene; or R 12 is absent;
  • R 13 is selected from: Ci-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: Ci-C 6 alkoxy, Ci-C 6 alkyl, C]-C 6 alkylamino, Q-C 6 alkylsulfonyl, amino, C 3 -C 7 cycloalkyl, cyano, C 2 -C 8 dialkylamino, Ci-C 6 haloalkyl, halogen, and hydroxyl;
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: Ci-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Ci-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: Q-C 6 alkoxycarbonyl, Q-C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said Q- C 6 alkyl and aryl are optionally substituted with one substituent selected from: C 1 -C 6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH-, -C(O)-, C 1 -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with C 1 -C 6 alkyl; or R 15 is absent;
  • R 16 is C 1 -C 6 alkylene; or R 16 is absent;
  • R 17 is selected from: H, C 1 -C 6 alkoxy, Q-C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- Q-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -C n bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, C 1 -C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said C 1 -C 6 alkylamino, aryl, arylamino
  • R 9 is selected from H, Ci-C 6 alkyl, and C 3 -C 7 cycloalkyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-Q-C 6 -alkoxy, Q-C 6 alkoxy, C 1 -C 6 alkyl, aryl, carbo-Q-C 6 - alkoxy, C 1 -C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl; wherein said aryl, Ci-C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ie and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 7 is -R 10 -R n -R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1,1-dimethylmethylene, ethylene, methylene, 1 ,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is methylene; or R 12 is absent;
  • R 13 is selected from: C]-C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, bromo, chloro, iodo, methoxy, cyano, methyl, tert- butyl, isopropyl, hydroxyl, ethyl, heptafluoropropyl, cyclobutyl, trifluoromethyl, cyclopropyl, dimethylamino, methoxy, ethoxy, methylamino, propyl, amino, and methanesulfonyl; R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: C]-C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Q-C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: methyl, tert-butyl, ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4-fluoro-phenyl, tert- butoxycarbonyl, carboxy, methoxymethyl, hydroxyethyl, tetrahydro-furanyl, 3H- imidazolylmethyl, hydroxyl, pyrrolidinyl, cyclopropyl, sec-butyl, 2,2,2-trifluoroethyl, 2- fluoropropan-2-yl, l,l,l,3,3,3-hexafluor
  • R 15 is selected from: -C(O)NH-, -C(O)-, -C(O)O-, C, -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with Ci-C 6 alkyl; or R 15 is absent;
  • R 16 is selected from: ethylene and methylene; or R 16 is absent;
  • R 17 is selected from: H, Ci-C 6 alkoxy, C,-C 6 alkyl, C r C 6 alkylamino, C r C 6 alkylcarboxamide, C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- C]-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, Ci-C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said C r C 6 alkylamino, amino, aryl, arylamino, aryl
  • R 9 is selected from H, C 1 -C 6 alkyl, and C 3 -C 7 cycloalkyl; or R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-Ci-C 6 -alkoxy, Ci-C 6 alkoxy, Ci-C 6 alkyl, aryl, carbo-Ci-C 6 - alkoxy, Ci-C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl;
  • aryl, C 1 -C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, C r C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ie and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 7 is -R I0 -R ⁇ -R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1,1-dimethylmethylene, ethylene, methylene, 1 ,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is methylene; or R 12 is absent; and R 13 is selected from: C 1 -C 6 alkyl, aryl, C 3 -C 7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said Ci-C 6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: fluoro, bromo, chloro, methoxy, cyano, methyl, tert-butyl, isopropyl, hydroxyl, ethyl, heptafluoropropyl, cyclobutyl, trifluoromethyl, cyclopropyl, dimethylamino, methoxy, ethoxy, methylamino, propyl, amino, and methanesulfonyl;
  • R 8 is -R I4 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: C 1 -C 6 alkylene, C 3 -C 7 cycloalkenylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said Ci -C 6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: methyl, tert-butyl, ethyl, tetrahydro-2H-pyranyl, isopropyl, benzyl, pyridinyl, hydroxymethyl, 4-fluoro-phenyl, tert- butoxycarbonyl, carboxy, methoxymethyl, hydroxyethyl, tetrahydro-furanyl, 3H- imidazolylmethyl, hydroxyl, pyrrolidinyl, and cyclopropyl; or R 14 is absent;
  • R 15 is selected from: -C(O)NH-, -C(O)-, Ci -C 6 alkylene, C 3 -C 7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with methyl; or R 15 is absent;
  • R 16 is selected from: ethylene and methylene; or R 16 is absent;
  • R 17 is selected from: H, Ci-C 6 alkoxy, Q-C 6 alkyl, C,-C 6 alkylamino, Q-C 6
  • alkylcarboxamide C 2 -C 6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo- C]-C 6 -alkoxy, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkylamino, C 2 -C 8 dialkylamino, C 2 -C 8 dialkylsulfonamide, Ci -C 6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said Ci-C 6 alkylamino, aryl, arylamino, aryloxy, C 5 -Cn bicycloalkyl, C 3 -C 7 cycloalkyl, C 3 -C 7
  • cycloalkylamino, heteroaryl, heterobicyclyl, heterocyclyl, and ureyl are each optionally substituted with one or more substituents selected from: amino, 1-tert-butoxycarbonylamino, methyl, 1 -tert-butoxycarbonyl, ethyl, hydroxyl, isopropyl, tert-butyl, fluoro, chloro, methoxy, methanesulfonyl, carboxy, trifluoromethoxy, difluoromethoxy, dimethylamino,
  • R 9 is selected from H, Q-C 6 alkyl, and C 3 -C 7 cycloalkyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: carbo-Ci-C 6 -alkoxy, Q-C 6 alkoxy, Q-C 6 alkyl, aryl, carbo-Q-C 6 - alkoxy, C 1 -C 6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl; wherein said aryl, C 1 -C 6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, halogen, and hydroxyl.
  • Some embodiments of the present invention pertain to compounds of Formula Ie and pharmaceutically acceptable salts, solvates, and hydrates thereof:
  • R 7 is -R 10 -R u -R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1,1-dimethylmethylene, ethylene, methylene, 1,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is 1,1-dimethyl-methylene; or R 12 is absent;
  • R 13 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 2-fluoro-4- methanesulfonyl-phenyl, 2,6-difluoro-phenyl, 2,5-difluoro-phenyl, 4-methoxy-phenyl, 4-cyano- phenyl, 4-fluoro-phenyl, phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, o-tolyl, tert-buty ⁇ , isopropyl, 2,2-dimethylpropyl, hydroxyl, 2-hydroxy-2-methylpropyl, l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydrothiopyran-4-yl, morpholin-4-yl, te
  • R 14 is selected from: methylene, ethylene, 1,1-cyclopropylene, 1,1 -dimethyl -methylene, 1,1-cyclobutylene, tert-buty ⁇ -methylene, 1 -methyl-4,4-piperidinylene, 4,4-tetrahydro-2H- pyranylene, methyl-methyl ene, 1,1-cyclohexylene, 1 ,2-cyclohexylene, 1,1 -dimethyl -ethylene, 1- tert-butyl-ethylene, 1 -ethyl -ethylene, 1 -methyl-ethylene, l-(tetrahydro-2H-pyran-4-yl)-ethylene, isopropyl-methylene, 1,1-cyclopentylene, benzyl -methylene, 4,4-cyclopent-l-enyl ene, 1,1- dioxo-hexahydro-1 ⁇ 6 -4,4-thiopyranylene, 1 -tert-but
  • R 15 is selected from: 1,3-pyrrolidinylene, 1 ,4-piperidinylene, 2,6-pyridinylene, 1,3- azetidinylene, -C(O)NH-, -C(O)-, -C(O)O-, 1 ,2-pyrrolidinylene, 2,4-morpholinylene, ethylene, methylene, 1,1-cyclopentylene, 4,4-tetrahydro-2H-pyranylene, 3,3-tetrahydro-thiophenylene, 1,1-cyclopropylene, 1 -methyl -4 ,4-piperidinylene, and l-oxo-tetrahydro-l ⁇ 4 -3,3-thiophenylene; or R 15 is absent;
  • R 16 is selected from: ethylene and methylene; or R 16 is absent; and R 17 is selected from: H, amino, 1-tert-butoxycarbonylamino, morpholin-4-yl, 4-methyl- piperidin-1-yl, piperidin-4-yl, l-tert-butoxycarbonyl-piperidin-3-yl, tetrahydro-thiopyran-4-yl, l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl, tetrahydro-pyran-4-yl, pyrrolidin-1-yl, ⁇ -tert- butoxycarbonyl-azetidin-3-yl, 2,6-dimethyl-mo ⁇ holin-4-yl, piperidin-1-yl, ⁇ -tert- butoxycarbonyl-piperidin-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl,
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-1 -yl, hexahydro-pyrrolo[l ,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomorpholin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l-yl, 4-hydroxy-piperidin- 1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin- 2-yl, 7-methoxy-3,4-dihydro-lH-iso
  • R 7 is -R 10 -R ⁇ -R 12 -R 13 ; wherein:
  • R 10 is selected from: 1,1-dimethylethylene, 1,1-dimethylmethylene, ethylene, methylene, 1 ,4-piperidinylene, 2,5-pyrazinylene, and 2,4-pyridinylene; or R 10 is absent;
  • R 11 is selected from: -C(O)NH- and methylene; or R 11 is absent;
  • R 12 is 1,1-dimethyl-methylene; or R 12 is absent;
  • R 13 is selected from: 2,4-difluoro-phenyl, 2,4-dichloro-phenyl, 2-fluoro-4- methanesulfonyl-phenyl, 2,6-difluoro-phenyl, 2,5-difluoro-phenyl, 4-methoxy-phenyl, 4-cyano- phenyl, 4-fluoro-phenyl, phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, o-tolyl, tert-buty ⁇ , isopropyl, 2,2-dimethylpropyl, hydroxyl, 2-hydroxy-2-methylpropyl, l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl, 1,1 -dioxo-hexahydro-1 ⁇ 6 -thiopyran-4-yl, tetrahydrothiopyran-4-yl, mo ⁇ holin-4-yl, te
  • R 8 is -R 14 -R 15 -R 16 -R 17 ; wherein:
  • R 14 is selected from: methylene, ethylene, 1,1-cyclopropylene, 1,1 -dimethyl -methylene,
  • R 15 is selected from: 1,3-pyrrolidinylene, 1,4-piperidinylene, 2,6-pyridinylene, 1,3- azetidinylene, -C(O)NH-, -C(O)-, 1 ,2-pyrrolidinylene, 2,4-mo ⁇ holinylene, ethylene, methylene, 1,1-cyclopentylene, 4,4-tetrahydro-2H-pyranylene, 3,3-tetrahydro-thiophenylene, 1,1- cyclopropylene, 1 -methyl -4,4-piperidinylene, and l-oxo-tetrahydro-l ⁇ 4 -3,3-thiophenylene; or R 15 is absent;
  • R 16 is selected from: ethylene and methylene; or R 16 is absent;
  • R 17 is selected from: ⁇ , amino, l-ferf-butoxycarbonylamino, morpholin-4-yl, 4-methyl- piperidin-1-yl, piperidin-4-yl, l-tert-butoxycarbonyl-piperidin-3-yl, tetrahydro-thiopyran-4-yl, l-oxo-hexahydro-l ⁇ 4 -thiopyran-4-yl, tetrahydro-pyran-4-yl, pyrrolidin-1-yl, ⁇ -tert- butoxycarbonyl-azetidin-3-yl, 2,6-dimethyl-morpholin-4-yl, piperidin-1-yl, l-tert- butoxycarbonyl-piperidin-4-yl, l,l-dioxo-hexahydro-l ⁇ 6 -thiopyran-4-yl, tetrahydro-furan-2-yl, 1 -ethy
  • R 9 is selected from H, methyl, tert-butyl, and cyclobutyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-l-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomo ⁇ holin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l -yl, 4-hydroxy-piperidin- 1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin- 2-yl, 7-methoxy-3,4-dihydro-lH
  • Some embodiments of the present invention pertain to compounds of Formula Ie and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 7 is selected from: 2,4-difluoro-phenyl, 5-bromo-pyridin-2-yl, 4-cyano-phenyl, pyridin-3-yl, pyridin-2-yl, 5-thiazol-2-yl-pyridin-2-yl, 5-trifluoromethyl-pyridin-2-yl, 5-o-tolyl- pyridin-2-yl, 5-dimethylamino-pyrazin-2-yl, 2,4-dichloro-phenyl, 5-isopropyl-pyridin-2-yl, 5- methyl-pyridin-2-yl, 5-(4-methoxy-phenyl)-pyridin-2-yl, 2-fluoro-4-methanesulfonyl-phenyl, 2- fluoro-phenyl, 5-chloro-pyridin-2-yl, 5-bromo-pyridin-3-yl, tert-butyl, 2-methoxy-pyridin-4
  • R 8 is selected from: H, 2-methyl-2-morpholin-4-yl-propyl, l-hydroxymethyl-2,2- dimethyl-propyl, 2-(/er/-butoxycarbonylamino)cyclohexyl, 1 -phenyl -cyclopropyl, 5- trifluoromethyl-pyridin-2-yl, 1 -methyl- 1 -phenyl-ethyl, 1 -(2-methoxy-ethyl)-pyrrolidin-3 - ylmethyl, 1 -(methoxycarbonyOcyclopropyl, tetrahydro-pyran-4-ylmethyl,
  • R 9 is selected from ⁇ , methyl, /ert-butyl, and cyclobutyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl-pyrrolidin-l-yl, 2- pyridin-2-yl-thiomo ⁇ holin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol- 1 -yl, 4-hydroxy-piperidin- 1-yl, hexahydro-pyrrolo[l ,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin- 2-yl, 7-methoxy-3,4-dihydro-lH
  • Some embodiments of the present invention pertain to compounds of Formula Ie and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
  • R 7 is selected from: 2,4-difluoro-phenyl,5-bromo-pyridin-2-yl, 4-cyano-phenyl, pyridin- 3-yl, pyridin-2-yl, 5-thiazol-2-yl-pyridin-2-yl, 5-trifluoromethyl-pyridin-2-yl, 5- ⁇ -tolyl-pyridin- 2-yl, 5-dimethylamino-pyrazin-2-yl, 2,4-dichloro-phenyl, 5-isopropyl-pyridin-2-yl, 5 -methyl - pyridin-2-yl, 5-(4-methoxy-phenyl)-pyridin-2-yl, 2-fluoro-4-methanesulfonyl-phenyl, 2-fiuoro- phenyl, 5-chloro-pyridin-2-yl, 5-bromo-pyridin-3-yl, tert-butyl, 2-meth
  • R 8 is selected from: H, 2-methyl -2 -morpholin-4-yl -propyl, l-hydroxymethyl-2,2- dimethyl-propyl, 2-(ter/-butoxycarbonylamino)cyclohexyl, 1-phenyl-cyclopropyl, 5- trifluoromethyl-pyridin-2-yl, 1-methyl-l-phenyl-ethyl, l-(2-methoxy-ethyl)-pyrrolidm-3- ylmethyl, 1 -(methoxycarbonyl)cyclopropyl, tetrahydro-pyran-4-ylmethyl,
  • R 9 is selected from ⁇ , methyl, tert-butyl, and cyclobutyl; or
  • R 8 and R 9 together with the nitrogen atom to which they are both bonded form 4- cyclohexylmethyl-piperazin-1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 5,7-dihydro- pyrrolo[3,4-b]pyridin-6-yl, 4-methoxy-2,3-dihydro-indol-l-yl, 2-phenyl -pyrrolidin-1-yl, 2- pyridin-2-yl-thiomo ⁇ holin-4-yl, 2-hydroxymethyl-2,3-dihydro-indol-l -yl, 4-hydroxy-piperidin- 1-yl, hexahydro-pyrrolo[l,2-a]pyrazin-2-yl, 7-(methoxycarbonyl)-3,4-dihydro-lH-isoquinolin- 2-yl, 7-methoxy-3,4-dihydro-lH-
  • Some embodiments of the present invention include every combination of one or more compounds selected from the following group, wherein the Compound Number in bold directly preceding the chemical name is used elsewhere in this disclosure:
  • Compound 162 (la/?,5ai?)-2-(2,4-Difluoro-phenyl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid (2-hydroxy-2-pyridin-2-yl-ethyl)-amide;
  • Compound 163 l-(2,4-Difluoro-phenyl)-3b,4,4a,5-tetrahydro-lH-cyclopropa[3,4]cyclopenta[l,2- c]py ⁇ azole-3-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
  • Compound 164 (laR,5a/?)- 2-(4-Fluoro-phenyl)-la,2,5,5a-tetrahydro-lH-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid
  • Compound 417 (la/?,5ai?)-2-(4-Methoxy-phenyl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
  • Compound 418 (laR,5aR)-2-(2,4-Difluoro-phenyl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid [l-(4-methoxy-phenyl)-cyclobutyl]-amide;
  • Compound 568 (la ⁇ ,5a/?)-2-(5-Methyl-py ⁇ azin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid (2 -hydroxy- l,l-dimethyl-ethyl)-amide;
  • Compound 569 ((lai?,5a ⁇ )-2-/ert-Butyl-la,2,5,5a-tetrahydro-lH-2,3-diaza-cyclopropa[a]pentalen-4-yl)-(2- phenyl-mo ⁇ holin-4-yl)-methanone;
  • Compound 570 (5)-2- ⁇ [(la/?,5a ⁇ )-2-(2,4-Difluoro- phenyO-la ⁇ a-tetrahydro-lH ⁇ -diaza-cyclopropafajpentalene ⁇ -carbon
  • Compound 703 Phosphoric acid mono-((S)-3,3-dimethyl-2- ⁇ [(la/?,5ai?)-2-(4-oxy-pyrazin-2- yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza-cyclopropa[a]pentalene-4-carbonyl]-amino ⁇ -butyl) ester;
  • Compound 704 (lai?,5ai?)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid ((S)-2,2-dimethyl- 1 -methylcarbamoyl-propyl)-amide;
  • Compound 705 ( 1 a/?,5a/?)-2-(4-Oxy-pyrazm-2-yl)- 1 a,2,5 ,
  • Compound 709 ⁇ [(laS,5aS)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carbonyl]-amino ⁇ -pyridin-2-yl-acetic acid methyl ester;
  • Compound 710 (laS',5a5)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid (methylcarbamoyl-pyridin-2-yl-methyl)-amide;
  • Compound 711 ⁇ [(la/?,5afl)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carbonyl]-amino ⁇ -pyridin-2-yl-acetic acid methyl ester;
  • Compound 712 (la5',5a 1 S)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid ((S)-2,2-dimethyl-l -morpholin-4-ylmethyl-propyl)- amide;
  • Compound 713 (la/?,5aJ?)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,
  • Compound 753 ( 1 aR,5ai?)-2-(4-Oxy-pyrazin-2-yl)- 1 a,2,5 ,5a-tetrahydro- lH-2,3 -diaza- cyclopropa[a]pentalene-4-carboxylic acid (l-pyridin-2-yl-cyclopropyl)-amide; Compound 754: (laS,5a5)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza-cyclopropa[a]pentalene-4- carboxylic acid [l-(4-fluoro-phenyl)-cyclobutyl]-amide; Compound 755: (lai?,5a/?)-2-(4-Oxy- pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza-cyclopropa
  • Compound 816 (la/?,5a/?)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid [l-(2-fluoro-phenyl)-cyclobutyl]-amide;
  • Compound 817 (laS,5aS)-2-(4-Oxy-pyrazin-2-yl)-la,2,5,5a-tetrahydro-lH-2,3-diaza- cyclopropa[a]pentalene-4-carboxylic acid [l-(2-fluoro-phenyl)-cyclobutyl]-amide;
  • Compound 818 (laR,5a/?)-2-Pyrazin-2-yl-la,2,5,5a-tetrahydro-lH-2,3-diaza-cyclopropa[a]pentalene-4-
  • chemical genera of the present invention and individual compounds encompass all pharmaceutically acceptable salts, solvates, and particularly hydrates, thereof.
  • the compounds of the Formula Ia of the present invention may be prepared according to relevant published literature procedures that are used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter in the working Examples. Protection and deprotection may be carried out by procedures generally known in the art (see, for example, Greene, T. W. and Wuts, P. G. M., Protecting Groups in Organic Synthesis, 3 rd Edition, 1999 [Wiley]).
  • the present invention embraces each diastereoisomer, each enantiomer and mixtures thereof of each compound and generic formulae disclosed herein just as if they were each individually disclosed with the specific stereochemical designation for each chiral carbon. Separation of the individual isomers (such as, by chiral HPLC, recrystallization of diastereoisomeric mixtures and the like) or selective synthesis (such as, by enantiomeric selective syntheses and the like) of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art.
  • the compounds disclosed herein are useful in the treatment of several additional diseases and disorders, and in the amelioration of symptoms thereof. Without limitation, these include the following: l. PAIN.
  • analgesic properties of cannabinoids have been recognized for many years.
  • animal studies have demonstrated that the CIVCB 2 agonists anandamide, THC, CP55,940 and WIN 55212-2 are effective against acute and chronic pain from chemical, mechanical, and thermal pain stimuli (reviewed in Walker and Huang (2002) Pharmacol. Ther. 95:127-135; reviewed in Pacher, P et al. (2006) Pharmacol. Rev. 58(3): 389-462).
  • topical administration of the CBi/CB 2 agonist HU-210 attenuates capsaicin-induced
  • hyperalgesia and allodynia (Rukwied, R. et al. (2003) Pain 102:283-288), and co-administration of the CB 1 ZCB 2 agonist THC and cannabidiol (nabiximols, trademark Sativex®) provides relief from cancer-associated pain (GW Pharmaceuticals press release Jan 19, 2005, Jun 19, 2007) and multiple-sclerosis-associated pain and spasticity (GW Pharmaceuticals press release Sept 27, 2005, Mar 11, 2009).
  • CB 1 activation by exogenous administration of a CB 1 agonist arachidonyl-2-chloroethylamide reduces pain
  • CB 2 also plays a role in mediating analgesic effects of cannabinoids (reviewed in Guindon and Hohmann (2008) Br. J. Pharmacol. 153:319-334).
  • AM 1241 also reverses tactile and thermal hypersensitivity in rats following ligation of spinal nerves in the chronic constriction injury model of neuropathic pain (Malan, T. P. et al. (2001) Pain 93:239-245; (2004), M. M. et al. (2003) Proc. Natl. Acad. Sd. 100(18):10529-10533), an effect which is inhibited by treatment with the CB 2 -selective antagonist AM630 (Ibrahim, M. M. et al. (2005) Proc. Natl. Acad. ScL 102(8):3093-8).
  • CB 2 -selective agonist GW405833 administered systemically significantly reverses hypersensitivity to mechanical stimuli in rats following ligation of spinal nerves (Hu, B. et al. (2009) Pain 143:206-212).
  • CB 2 -selective agonists have also been demonstrated to attenuate pain in experimental models of acute, inflammatory, and neuropathic pain, and hyperalgesia.
  • CB 2 -specif ⁇ c agonists and/or CBi/CB 2 agonists find use in the treatment and/or prophylaxis of acute nociception and inflammatory hyperalgesia, as well as the allodynia and hyperalgesia produced by neuropathic pain.
  • these agonists are useful as an analgesic to treat pain arising from autoimmune conditions; allergic reactions; bone and joint pain; muscle pain; dental pain; nephritic syndrome; scleroderma; thyroiditis; migraine and other headache pain; pain associated with diabetic neuropathy; fibromyalgia, HlV-related neuropathy, sciatica, and neuralgias; pain arising from cancer; and pain that occurs as an adverse affect of therapeutics for the treatment of disease.
  • agonists Of CB 1 that are unable to cross the blood brain barrier still find use in the treatment and/or prophylaxis of acute pain, inflammatory pain, neuropathic pain, and hyperalgesia.
  • DISORDERS OF THE IMMUNE SYSTEM Autoimmune disorders. Cannabinoid receptor agonists have been demonstrated to attenuate aberrant immune responses in autoimmune disorders, and in some cases, to provide protection to the tissue that is being inappropriately targeted by the immune system.
  • MS Multiple Sclerosis
  • EAE Experimental Autoimmune Encephalomyelitis
  • CB 1 - selective agonist WIN 55212-2 provides significant neuroprotection in the experimental allergic uveitis (EAU) model in mice (Pryce, G. et al.
  • CB 2 - selective agonist HU-308 markedly reduces the recruitment of immature myeloid cells and T cells, microglial and infiltrating myeloid cell proliferation, and axonal loss in the EAE model (Palazuelos, J. et al. (2008). J. Biol. Chem. 283(19): 13320-9).
  • the CB,/CB 2 agonist WIN 55212-2 significantly inhibits leukocyte rolling and adhesion in the brain in the EAE mouse model, an effect that is blocked by the CB 2 -selective antagonist SR144528 but not the CB ⁇ selective antagonist SR141716A (Ni, X.
  • CB 2 -selective agonists and/or CB 1 ZCB 2 agonists find use in the treatment and/or prophylaxis of Multiple Sclerosis and related autoimmune demyelinating diseases, e.g. Guillan-Barre syndrome, polyradiculoneuropathy and chronic inflammatory demyelination.
  • the autoimmune disease Rheumatoid Arthritis is a chronic, systemic inflammatory disorder of the skeletal system that principally attacks the joints to produce an inflammatory synovitis and that often progresses to destruction of the articular cartilage and ankylosis of the joints.
  • the CB 1 ZCB 2 agonists WIN 55212-2 and HU-210 significantly inhibit IL-I alpha-stimulated proteoglycan and collagen degradation in bovine nasal cartilage explants in vitro (Mbvundula, E. et al. (2006) J. Pharm. and Pharmacol. 58:351-358).
  • CB 2 -selective agonists and/or CB 1 ZCB 2 agonists find use in the treatment andZor prophylaxis of autoimmune arthritic diseases, for example, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis, and reactive arthritis.
  • Type 1 Hypersensitivity and Allergic response Cannabinoid receptor agonists have been demonstrated to attenuate aberrant immune responses in allergic reactions as well.
  • type- 1, or immediate, hypersensitivity plasma cells that have been activated by an allergen secrete IgE antibodies, which bind to Fc receptors on the surface of tissue mast cells and blood basophils and eosinophils. Repeated exposure to the same allergen results in cross-linking of the bound IgE on sensitized cells, resulting in secretion of pharmacologically active mediators such as histamine, leukotriene and prostaglandin. These mediators are responsible for the symptoms associated with allergies, including vasodilation and increased permeability, smooth muscle spasms, and leukocyte extravasation.
  • Topical administration of the CB 1 ZCB 2 agonist HU-210 reduces these histamine-induced responses in human skin (Dvorak, M. et al. (2003) Inflamm. Res. 52:238-245).
  • subcutaneous injection of CB,/CB 2 agonist THC or increased levels of endogenous cannabinoids reduces cutaneous inflammation and the pruritis (itch) associated with it in a mouse model for allergic contact dermatitis.
  • CB 2 -selective agonists and/or CB,/CB 2 agonists find use in the treatment of allergic reactions including atopic dermatitis (pruritis/itch), urticaria (hives), asthma, conjunctivitis, allergic rhinitis (hay fever), and anaphylaxis.
  • CB 2 agonists have been demonstrated to attenuate inflammation in the CNS.
  • administration of CB 2 agonists prevents the activation of microglia in rodent models of Alzheimer's Disease (Ashton J. C, et al. (2007) Curr. Neuropharmacol. 5(2):73-80).
  • administration of CB 2 agonists reduces the volume of infarcts by 30% in a rodent occlusion model of stroke (Zhang, M. et al. (2007) J. Cereb. Blood Flow Metab. 27: 1387-96).
  • CB 2 agonists find use in the treatment and/or prophylaxis of neuropathologies associated with CNS inflammation, e.g. Alzheimer's, stroke- induced damage, dementia, ALS, and HIV.
  • CB 2 is expressed in macrophages and T cells in atherosclerotic plaques, and the CBi/CB 2 agonist THC reduces the progression of atherosclerosis in ApoE knockout mice, a well studied mouse model of atherosclerosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2010/002360 2009-08-28 2010-08-27 Cannabinoid receptor modulators Ceased WO2011025541A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
EA201270336A EA023586B1 (ru) 2009-08-28 2010-08-27 Модуляторы каннабиноидных рецепторов, фармацевтическая композиция, их содержащая, и способы их применения
AU2010286988A AU2010286988B2 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
EP22160034.9A EP4036089A1 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
KR1020177016103A KR20170072358A (ko) 2009-08-28 2010-08-27 칸나비노이드 수용체 조절제
KR1020217014027A KR20210057213A (ko) 2009-08-28 2010-08-27 칸나비노이드 수용체 조절제
MX2012002499A MX2012002499A (es) 2009-08-28 2010-08-27 Moduladores de receptor canabinoide.
KR1020227032376A KR102682216B1 (ko) 2009-08-28 2010-08-27 칸나비노이드 수용체 조절제
JP2012526732A JP5746698B2 (ja) 2009-08-28 2010-08-27 カンナビノイド受容体モジュレーター
EP22159802.2A EP4036082A1 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
KR1020187029637A KR20180115807A (ko) 2009-08-28 2010-08-27 칸나비노이드 수용체 조절제
SG2012013967A SG178907A1 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
CA2770866A CA2770866C (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
NZ598288A NZ598288A (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
IN2474DEN2012 IN2012DN02474A (https=) 2009-08-28 2010-08-27
US13/392,074 US8778950B2 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
EP10757325A EP2470508A1 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
KR1020207001281A KR20200008045A (ko) 2009-08-28 2010-08-27 칸나비노이드 수용체 조절제
KR1020127007857A KR101749778B1 (ko) 2009-08-28 2010-08-27 칸나비노이드 수용체 조절제
EP18150186.7A EP3363788A1 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
CN201080049159.2A CN102596913B (zh) 2009-08-28 2010-08-27 大麻素受体调节剂
BR112012008159A BR112012008159A2 (pt) 2009-08-28 2010-08-27 moduladores de receptor canabinoide
IL218130A IL218130A (en) 2009-08-28 2012-02-15 Compounds containing pyrazole that are administered to bicyclo [0.1.3] hexane and pharmaceutical preparations containing them
US13/616,918 US9944606B2 (en) 2009-08-28 2012-09-14 Cannabinoid receptor modulators
US15/912,700 US20180354907A1 (en) 2009-08-28 2018-03-06 Cannabinoid receptor modulators
US16/580,697 US11214548B2 (en) 2009-08-28 2019-09-24 Cannabinoid receptor modulators
US17/024,752 US11746091B2 (en) 2009-08-28 2020-09-18 Cannabinoid receptor modulators
US17/520,952 US20220306586A1 (en) 2009-08-28 2021-11-08 Cannabinoid receptor modulators

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27550609P 2009-08-28 2009-08-28
US61/275,506 2009-08-28
US39658810P 2010-05-28 2010-05-28
US61/396,588 2010-05-28
US40014610P 2010-07-22 2010-07-22
US61/400,146 2010-07-22

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/392,074 A-371-Of-International US8778950B2 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators
US13/616,918 Division US9944606B2 (en) 2009-08-28 2012-09-14 Cannabinoid receptor modulators
US13/616,918 Continuation US9944606B2 (en) 2009-08-28 2012-09-14 Cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
WO2011025541A1 true WO2011025541A1 (en) 2011-03-03

Family

ID=43127457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002360 Ceased WO2011025541A1 (en) 2009-08-28 2010-08-27 Cannabinoid receptor modulators

Country Status (19)

Country Link
US (6) US8778950B2 (https=)
EP (4) EP3363788A1 (https=)
JP (5) JP5746698B2 (https=)
KR (6) KR102682216B1 (https=)
CN (2) CN103539785B (https=)
AR (1) AR077991A1 (https=)
AU (1) AU2010286988B2 (https=)
BR (1) BR112012008159A2 (https=)
CA (1) CA2770866C (https=)
EA (1) EA023586B1 (https=)
HK (1) HK1259082A1 (https=)
IL (1) IL218130A (https=)
IN (1) IN2012DN02474A (https=)
MX (1) MX2012002499A (https=)
NZ (1) NZ598288A (https=)
SG (3) SG178907A1 (https=)
TW (1) TWI503316B (https=)
WO (1) WO2011025541A1 (https=)
ZA (1) ZA202205142B (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116277A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116279A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116276A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
WO2014097188A1 (en) 2012-12-21 2014-06-26 C4T S.C. A.R.L. Compounds of 2,3-dihydro-4h-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
WO2018208848A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
EP3452037A4 (en) * 2016-04-10 2020-03-11 Arena Pharmaceuticals, Inc. METHODS OF TREATMENT WITH CB2 RECEPTOR AGONISTS
WO2021047583A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种三环吡唑衍生物及其制备
US11560422B2 (en) 2013-12-27 2023-01-24 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
US11591405B2 (en) 2014-09-17 2023-02-28 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US11746091B2 (en) 2009-08-28 2023-09-05 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP4378940A4 (en) * 2021-06-29 2024-09-04 Shenzhen Keye Life Technologies, Co., Ltd. POLYCYCLIC COMPOUND FOR INHIBITING RNA HELICASE DHX33 AND APPLICATION OF THE COMPOUND

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
JP5983714B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸プロドラッグの結晶形とその製造方法
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
CN109689045A (zh) 2016-05-04 2019-04-26 因美制药公司 大麻素的局部制剂在治疗大疱性表皮松解症和相关结缔组织病症中的用途
US12357604B2 (en) 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
EP3886845B1 (en) 2018-11-28 2024-09-04 Merck Sharp & Dohme LLC Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
JP7620024B2 (ja) 2020-09-24 2025-01-22 富士フイルム株式会社 複合パターンの製造方法、樹脂組成物、積層体の製造方法、及び、半導体デバイスの製造方法
CN114736173B (zh) * 2022-05-24 2024-06-11 无锡捷化医药科技有限公司 一种3-（二氟甲基）氧杂环丁烷-3-胺盐酸盐的制备方法
WO2025090133A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection
WO2025090587A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Cannabinoids compounds and their use in the treatment of neuronal disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259936A1 (en) 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
WO2006030124A1 (fr) * 2004-09-13 2006-03-23 Sanofi-Aventis Derives de pyrazole condense, leur preparation et leur application en therapeutique.
WO2006069242A2 (en) * 2004-12-23 2006-06-29 Arena Pharmaceuticals, Inc. Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders
WO2006129178A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
EP2343302A1 (en) 2004-07-12 2011-07-13 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
WO2006010379A1 (en) * 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
ATE459352T1 (de) 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
EP2091921A2 (en) 2006-11-03 2009-08-26 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
US8193369B2 (en) 2007-03-30 2012-06-05 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CN101686989B (zh) 2007-06-21 2016-10-19 卡拉治疗学股份有限公司 取代的咪唑并杂环
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
WO2010088050A2 (en) 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
IN2012DN02474A (https=) 2009-08-28 2015-08-21 Arena Pharm Inc
AU2012222149B2 (en) * 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US9597340B2 (en) * 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP2678330A1 (en) * 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259936A1 (en) 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
WO2006030124A1 (fr) * 2004-09-13 2006-03-23 Sanofi-Aventis Derives de pyrazole condense, leur preparation et leur application en therapeutique.
WO2006069242A2 (en) * 2004-12-23 2006-06-29 Arena Pharmaceuticals, Inc. Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders
WO2006129178A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
AGARWAL, N. ET AL., NAT. NEUROSCI., vol. 10, no. 7, 2007, pages 870 - 879
ASHTON J. C. ET AL., CURR. NEUROPHARMACOL., vol. 5, no. 2, 2007, pages 73 - 80
BERGE ET AL., JOURNAL OFPHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
CALIGNANO, A. ET AL., NATURE, vol. 394, 1998, pages 277 - 281
CALIGNANO, A. ET AL., NATURE, vol. 408, 2000, pages 96 - 101
COLLIER, T. L., J. LABELLED COMPD. RADIOPHARM., vol. 42, 1999, pages S264 - S266
DVORAK, M. ET AL., INFLAMM. RES., vol. 52, 2003, pages 238 - 245
EDWARD B. ROCHE: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
FURUSE, S. ET AL., ANESTHESIOLOGY, vol. 111, no. 1, 2009, pages 173 - 86
G. P. STAHLY, CRYSTAL GROWTH & DESIGN, vol. 7, no. 6, 2007, pages 1007 - 1026
GENNARO ET AL.: "The Science and Practice of Pharmacy, 20th Edition,", 2000, LIPPINCOTT WILLIAMS & WILKINS
GONCALVES, M. B. ET AL., MOL. CELL NEUROSCI., vol. 38, no. 4, 2008, pages 526 - 36
GREENE, T. W.; WUTS, P. G. M.: "Protecting Groups in Organic Synthesis, 3rd Edition,", 1999, WILEY
GUINDON; HOHMANN, BR. J. PHARMACOL., vol. 153, 2008, pages 319 - 334
HU, B. ET AL., PAIN, vol. 143, 2009, pages 206 - 212
IBRAHIM, M. M. ET AL., PROC. NATL. ACAD. SCI., vol. 100, no. 18, 2003, pages 10529 - 10533
IBRAHIM, M. M. ET AL., PROC. NATL. ACAD. SCI., vol. 102, no. 8, 2005, pages 3093 - 8
K.J. GUILLORY: "Polymorphism in Pharmaceutical Solids", vol. 95, 1999, MARCEL DEKKER, INC., article "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", pages: 202 - 209
KARSAK ET AL., SCIENCE, vol. 316, no. 5830, 2007, pages 1494 - 1497
LE BAS, M.-D., J. LABELLED COMPD. RADIOPHARM., vol. 44, 2001, pages S280 - S282
MALAN, T. P. ET AL., PAIN, vol. 93, 2001, pages 239 - 245
MANZANARES, J. ET AL., CURRENT NEUROPHARMACOLOGY, vol. 4, 2006, pages 239 - 57
MARESZ, K. ET AL., NAT. MED., vol. 13, no. 4, 2007, pages 492 - 497
MATSUDA, L. A., NATURE, vol. 346, 1990, pages 561 - 564
MBVUNDULA, E. ET AL., J. PHARM. AND PHARMACOL., vol. 58, 2006, pages 351 - 358
MORITA, K. ET AL., EUR. J. PHARMACAL., vol. 474, 2003, pages 269 - 272
MORITA, K. ET AL., EUR. J. PHARMACOL., vol. 474, 2003, pages 269 - 272
MUNRO, S. ET AL., NATURE, vol. 365, 1993, pages 61 - 65
NI, X. ET AL., MULT. SCLEROSIS, vol. 10, no. 2, pages 158 - 64
OFEK, O. ET AL., PROC. NATL. ACAD. SCI., vol. 103, no. 3, 2006, pages 696 - 701
OLEA-HERRERO ET AL., BRITISH JOURNAL OF CANCER, 18 August 2009 (2009-08-18)
PACHER, P ET AL., PHARMACOL. REV., vol. 58, no. 3, 2006, pages 389 - 462
PACHER, P. ET AL., PHARMACOL. REV., vol. 58, no. 3, 2006, pages 389 - 462
PALAZUELOS, J. ET AL., J. BIOL. CHEM., vol. 283, no. 19, 2008, pages 13320 - 9
PATEL, H. J. ET AL., BRITISH J. PHARMA., vol. 140, 2003, pages 261 - 8
PRYCE, G. ET AL., BRAIN, vol. 126, 2003, pages 2191 - 2202
RICHARDSON, J. D. ET AL., EUR. J. PHARMACOL., vol. 345, 1997, pages 145 - 153
RUKWIED, R. ET AL., PAIN, vol. 102, 2003, pages 283 - 288
STEFFENS, S. ET AL., NATURE, vol. 434, 2005, pages 782 - 786
SYNTHESIS, vol. 7, 1994, pages 701 - 702
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
WALKER; HUANG, PHARMACOL. THER., vol. 95, 2002, pages 127 - 135
WEI, Y. ET AL., MOL. VIS., vol. 15, 2009, pages 1243 - 51
WIDMER, M., J. NEUROSCI. RES., vol. 86, no. 14, 2008, pages 3212 - 20
ZHANG, M. ET AL., J CEREB. BLOOD FLOW METAB., vol. 27, 2007, pages 13 87 - 96
ZHU, G-D., J. ORG. CHEM., vol. 67, 2002, pages 943 - 948

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11746091B2 (en) 2009-08-28 2023-09-05 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) * 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
WO2012116277A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369A (zh) * 2011-02-25 2014-01-01 艾尼纳制药公司 大麻素受体调节剂
US12109219B2 (en) 2011-02-25 2024-10-08 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US20150126477A1 (en) * 2011-02-25 2015-05-07 Jayant Thatte Cannabinoid receptor modulators
US11771695B2 (en) 2011-02-25 2023-10-03 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US9458136B2 (en) 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US9492447B2 (en) 2011-02-25 2016-11-15 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
AU2012222146B2 (en) * 2011-02-25 2017-05-11 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
US9867822B2 (en) 2011-02-25 2018-01-16 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP3385252A1 (en) * 2011-02-25 2018-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP3395812A1 (en) 2011-02-25 2018-10-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
WO2012116279A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP4166552A1 (en) 2011-02-25 2023-04-19 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
US10183930B2 (en) 2011-02-25 2019-01-22 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
WO2012116276A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
US11560369B2 (en) 2011-02-25 2023-01-24 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US10981895B2 (en) 2011-02-25 2021-04-20 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US10632134B2 (en) 2011-02-25 2020-04-28 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора
WO2014097188A1 (en) 2012-12-21 2014-06-26 C4T S.C. A.R.L. Compounds of 2,3-dihydro-4h-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them
US11560422B2 (en) 2013-12-27 2023-01-24 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
US12152083B2 (en) 2014-09-17 2024-11-26 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US11591405B2 (en) 2014-09-17 2023-02-28 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
EP3452037A4 (en) * 2016-04-10 2020-03-11 Arena Pharmaceuticals, Inc. METHODS OF TREATMENT WITH CB2 RECEPTOR AGONISTS
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
WO2018208848A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
US12201633B2 (en) 2017-05-08 2025-01-21 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
WO2021047583A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种三环吡唑衍生物及其制备
TWI768464B (zh) * 2019-09-12 2022-06-21 大陸商四川海思科製藥有限公司 三環吡唑衍生物及其製備
CN114391010A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种三环吡唑衍生物及其制备
EP4378940A4 (en) * 2021-06-29 2024-09-04 Shenzhen Keye Life Technologies, Co., Ltd. POLYCYCLIC COMPOUND FOR INHIBITING RNA HELICASE DHX33 AND APPLICATION OF THE COMPOUND

Also Published As

Publication number Publication date
ZA202205142B (en) 2023-10-25
US11746091B2 (en) 2023-09-05
TWI503316B (zh) 2015-10-11
JP2022009408A (ja) 2022-01-14
JP2013503161A (ja) 2013-01-31
EA023586B1 (ru) 2016-06-30
KR20180115807A (ko) 2018-10-23
IN2012DN02474A (https=) 2015-08-21
SG10201901293RA (en) 2019-03-28
CN102596913B (zh) 2016-11-09
AU2010286988A1 (en) 2012-03-15
AU2010286988B2 (en) 2014-09-11
US8778950B2 (en) 2014-07-15
US9944606B2 (en) 2018-04-17
JP2018021074A (ja) 2018-02-08
KR20200008045A (ko) 2020-01-22
BR112012008159A2 (pt) 2016-03-01
KR20220132664A (ko) 2022-09-30
EP4036089A1 (en) 2022-08-03
US20200017448A1 (en) 2020-01-16
US20220306586A1 (en) 2022-09-29
CA2770866C (en) 2017-10-10
KR20210057213A (ko) 2021-05-20
KR102682216B1 (ko) 2024-07-04
EP2470508A1 (en) 2012-07-04
EA201270336A1 (ru) 2012-09-28
US20210188781A1 (en) 2021-06-24
US20120214766A1 (en) 2012-08-23
JP2020033387A (ja) 2020-03-05
TW201111366A (en) 2011-04-01
JP5746698B2 (ja) 2015-07-08
IL218130A0 (en) 2012-06-28
NZ598288A (en) 2014-02-28
SG178907A1 (en) 2012-04-27
US20180354907A1 (en) 2018-12-13
US20130165412A1 (en) 2013-06-27
KR101749778B1 (ko) 2017-06-21
HK1259082A1 (en) 2019-11-22
CN103539785B (zh) 2015-09-23
AR077991A1 (es) 2011-10-05
EP4036082A1 (en) 2022-08-03
JP2015145423A (ja) 2015-08-13
CN102596913A (zh) 2012-07-18
KR20140015131A (ko) 2014-02-06
IL218130A (en) 2016-02-29
CA2770866A1 (en) 2011-03-03
MX2012002499A (es) 2012-05-22
CN103539785A (zh) 2014-01-29
SG10201404925TA (en) 2014-10-30
EP3363788A1 (en) 2018-08-22
KR20170072358A (ko) 2017-06-26
US11214548B2 (en) 2022-01-04

Similar Documents

Publication Publication Date Title
US11746091B2 (en) Cannabinoid receptor modulators
US20170143704A1 (en) Cannabinoid receptor modulators
WO2012116277A1 (en) Cannabinoid receptor modulators
WO2012116278A1 (en) Cannabinoid receptor modulators
TWI829481B (zh) 雙環吲唑糖皮質素受體拮抗劑
HK40078299A (en) Cannabinoid receptor modulators
HK40011011A (en) Cannabinoid receptor modulators
BR112020013759A2 (pt) triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080049159.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10757325

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2770866

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 218130

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010286988

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2012526732

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/002499

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010286988

Country of ref document: AU

Date of ref document: 20100827

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2474/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20127007857

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010757325

Country of ref document: EP

Ref document number: 201270336

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13392074

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012008159

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012008159

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120227